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Genome-wide Association Study Identifies Eight Risk Loci and Implicates 
Metabo-Psychiatric Origins for Anorexia Nervosa 
 
Characterized primarily by low BMI, anorexia nervosa is a complex and serious illness1, 
affecting 0.9-4% of women and 0.3% of men2-4, with twin-based heritability estimates of 
50-60%5. Mortality rates are higher than other psychiatric disorders6, and outcomes are 
unacceptably poor7. Combining data from the Anorexia Nervosa Genetics Initiative 
(ANGI)8,9 and the Eating Disorders Working Group of the Psychiatric Genomics 
Consortium (PGC-ED), we conducted a genome-wide association study (GWAS) of 16,992 
anorexia nervosa cases and 55,525 controls, identifying eight significant loci. The genetic 
architecture of anorexia nervosa mirrors its clinical presentation showing significant 
genetic correlations with psychiatric disorders, physical activity, metabolic (including 
glycemic), lipid, and anthropometric traits, independent of the effects of common variants 
associated with BMI. Results further encourage a reconceptualization of anorexia nervosa 
as a metabo-psychiatric disorder. Explicating the metabolic component is a critical 
direction, and attention to both psychiatric and metabolic components may be key to 
improving outcomes. 
The first PGC-ED GWAS (3,495 cases, 10,982 controls) estimated the common genetic 
variant-based heritability of anorexia nervosa as ~20%, identified the first genome-wide 
significant locus, and reported significant genetic correlations (rg) between anorexia nervosa and 
psychiatric and metabolic/anthropometric phenotypes10. These rg pointed toward metabolic 
etiological factors, as they are robust to reverse causation although they could be mediated 
associations11 or reflect confounding processes12. To advance genomic discovery in anorexia 
10 
nervosa and further explore genetic correlations, we combined samples from ANGI8,9, the 
Genetic Consortium for Anorexia Nervosa (GCAN)/Wellcome Trust Case Control Consortium-3 
(WTCCC-3)13, and the UK Biobank14, quadrupling our sample size. 
Our GWAS meta-analysis included 33 datasets comprising 16,992 cases and 55,525 
controls of European ancestry from 17 countries (Supplementary Tables 1-4). We had 80% 
power to detect an odds ratio (OR) of 1.09-1.19 (additive model, 0.9% lifetime risk, α = 5 × 10-8, 
MAF 0.05–0.5). Typical of complex trait GWAS, we observed test statistic inflation (λ = 1.22) 
consistent with polygenicity, with no evidence of significant population stratification according 
to the LD intercept and attenuation ratio (Supplementary Results; Supplementary Fig. 1). 
Meta-analysis results were completed for autosomes and the X chromosome. We identified eight 
loci exceeding genome-wide significance (P < 5 × 10-8; Table 1 for loci; Fig. 1 for the 
Manhattan plot; Supplementary Figs. 2a-h and 3a-h for the forest and region plots). Many were 
near the threshold for significance, and no significant heterogeneity of SNP associations across 
cohorts was detected (P = 0.15-0.64; Supplementary Figs 2a-h). Conditional and joint analysis 
(GCTA-COJO)15 confirmed independence of the lead SNPs within the significant loci 
(Supplementary Table 5). The eight loci were annotated to identify known protein-coding 
genes (Supplementary Table 6; Supplementary Table 7 reports a gene look-up restricted to 
the single-gene loci). The previously reported PGC-ED genome-wide significant variant 
(rs4622308)10 on 12q13.2 did not reach genome-wide significance (P = 7.02 × 10-5); however, 
between-cohort heterogeneity was apparent (I2 = 53.7; Supplementary Fig. 4 and 
Supplementary Results). The OR was in the same direction in 22 (67%) of the cohorts (z = 
2.00, P = 0.05, 2-tailed). 
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Although GWAS findings are informative genome-wide, identifying strong hypotheses 
about their connections to specific genes is not straightforward. We evaluated three ways to 
“connect” anorexia nervosa GWAS loci to genes: regulatory chromatin interactions; relationship 
to brain expression QTLs (eQTLs; using a superset of CommonMind16 and GTEx17) and the 
standard approach of gene location within a GWAS locus. The significant anorexia nervosa loci 
implicated 121 brain-expressed genes, 74% by location, 55% by adult brain eQTL, 93% by 
regulatory chromatin interaction, and 58 genes by all three methods. Supplementary Figs. 5a-h 
show the eight GWAS loci, GENCODE gene models, adult brain regulatory chromatin 
interactions, brain eQTLs, and functional genomic annotations. 
Four single-gene loci were confirmed by eQTL, chromatin interaction, or both. These 
were the locus-intersecting genes CADM1 (locus 2 chr11:114.9-115.4 Mb, Supplementary Fig. 
5b), MGMT (locus 4, chr10:131.2-131.4 Mb, Supplementary Fig. 5d), FOXP1 (locus 5, 
chr3:70.6-71.0 Mb, Supplementary Fig. 5e) and PTBP2 (locus 6, chr1:96.6-97.2 Mb, 
Supplementary Fig. 5f). For locus 5, eQTL data implicated a distal gene, GPR27. One 
intergenic locus (locus 7, chr5:24.9-25.3 Mb, Supplementary Fig. 5g) had no eQTL or 
chromatin interactions whereas the other intergenic locus (locus 8, chr3:93.9-95.0 Mb, 
Supplementary Fig. 5h) had eQTL connections to PROS1 and ARL13B. Two complex 
multigenic loci had many brain-expressed genes and dense chromatin and eQTL interactions that 
precluded identification of any single gene (locus 1, chr3:47.5-51.3 Mb; locus 3, chr2:53.8-54.3 
Mb, Supplementary Figs. 5a and 5c). The clearest evidence and connections were for the 
single-gene loci intersecting CADM1, MGMT, FOXP1, and PTBP2 and we conclude these genes 
may play a role in anorexia nervosa etiology (Supplementary Results). 
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Supplementary Table 8 presents multi-trait analysis (GCTA-mtCOJO18 conditioning 
our genome-wide significant SNPs on associated variants in GWAS of BMI, type 2 diabetes, 
education years, HDL cholesterol, neuroticism, and schizophrenia. Seven loci appear to be 
independent. Locus 2 on chr11 may not be unique to anorexia nervosa and may be driven by 
genetic variation also associated with type 2 diabetes. 
Liability-scale SNP heritability (SNP-h2) was estimated with LD score regression 
(LDSC)19,20. Assuming a lifetime prevalence of 0.9-4%2-4, SNP-h2 was 11-17% (s.e. = 1%), 
supporting the polygenic nature of anorexia nervosa. Polygenic risk score (PRS) analyses using a 
leave-one-out approach indicated that the PRS captures ~1.7% of the phenotypic variance on the 
liability scale for discovery P = 0.5. We did not observe differences in polygenic architecture 
between anorexia nervosa subtypes with binge eating (2,381 cases, 10,249 controls) or without 
(2,262 cases, 10,254 controls) or between males (447 cases, 20,347 controls) and females 
(14,898 cases, 27,545 controls) (Methods, Supplementary Results, Supplementary Fig. 6, 
Supplementary Table 9). Similar to females, males in the highest PRS decile had 4.13 (95% CI: 
2.58-6.62) times the odds of anorexia nervosa than those in the lowest decile. Confirmation of 
these results requires larger samples. 
We tested SNP-based genetic correlations (SNP-rg) with external traits using bivariate 
LDSC19,20. Bonferroni-significant SNP-rg assorted into five trait categories: psychiatric and 
personality; physical activity; anthropometric; metabolic; and educational attainment 
(Supplementary Table 10). Fig. 2 presents Bonferroni-corrected positive SNP-rg with OCD 
(SNP-rg ± s.e. = 0.45 ± 0.08; P = 4.97 × 10-9), MDD (0.28 ± 0.07; P = 8.95 × 10-5), anxiety 
disorders (0.25 ± 0.05; P = 8.90 × 10-8), and schizophrenia (0.25 ± 0.03; P = 4.61 × 10-18). This 
pattern reflects observed comorbidities in clinical and epidemiological studies21,22. The newly-
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identified positive SNP-rg with physical activity (0.17 ± 0.05; P = 1.00 × 10-4) encourages 
further exploration of the refractory symptom of pathologically elevated activity in anorexia 
nervosa23. We note that the significant SNP-rg of anorexia nervosa with educational attainment 
(0.25 ± 0.03; P = 1.69 × 10-15) and related constructs was not seen for IQ24.  
Expanding our previous observations10, we present a palette of metabolic and 
anthropometric rg with anorexia nervosa more pronounced than in other psychiatric disorders. 
We observed significant negative SNP-rg with fat mass (-0.33 ± 0.03; P = 7.23 × 10-25), fat-free 
mass (-0.12 ± 0.03; P = 4.65 × 10-5), BMI (-0.32 ± 0.03; P = 8.93 × 10-25), obesity (-0.22 ± 0.03; 
P = 2.96 × 10-11), type 2 diabetes (-0.22 ± 0.05; P = 3.82 × 10-5), fasting insulin (-0.24 ± 0.06; P 
= 2.31 × 10-5), insulin resistance (-0.29 ± 0.07; P = 2.83 × 10-5), and leptin (-0.26 ± 0.06; P = 
4.98 × 10-5), and a significant positive SNP-rg with HDL cholesterol (0.21 ± 0.04; P = 3.08 × 10-
7). 
Systems biology analyses of our results revealed preliminarily interesting results 
(Methods, Supplementary Tables 11-13, Supplementary Figs. 7-15). Gene-wise analysis with 
MAGMA prioritized 79 Bonferroni-significant genes, most within the multigenic locus on chr3 
(Supplementary Table 11). MAGMA indicated an association with NCAM1  (Supplementary 
Table 11) the expression of which increases in response to food restriction in a rodent activity-
based anorexia nervosa model25. Partitioned heritability analysis showed, as with other GWAS26, 
considerable enrichment of SNP-h2 in conserved regions (fold enrichment = 24.97, s.e. = 3.29, P 
= 3.32 × 10-11; Supplementary Fig. 7)27. Cell type group-specific annotations revealed that the 
overall SNP-h2 is significantly enriched for CNS tissue (Supplementary Fig. 8). One biological 
pathway was significant: GO:positive_regulation_of_embryonic_development (32 genes, P = 
1.39 × 10-7; Supplementary Table 12), which contains two Bonferroni-significant genes on 
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chr3, CTNNB1 and DAG1. CTNNB1 encodes catenin beta-1, which is part of adherens junctions, 
and DAG1 encodes dystroglycan, a receptor which binds extracellular matrix proteins28. DAG1 
falls within locus 1 (47.5-51.3 Mb). This pathway points to a potential role of developmental 
processes in the etiology of this complex phenotype (although this is currently speculative). 
Genes associated with anorexia nervosa were enriched for expression in most brain tissues, 
particularly the cerebellum, which has a notably high proportion of neurons29 (Supplementary 
Fig. 9). Among 24 brain cell types from mouse brain, significant enrichment was found for 
medium spiny neurons and pyramidal neurons from hippocampal CA1 (Supplementary Fig. 
10). Both medium spiny and pyramidal neurons are linked to feeding behaviors including food 
motivation and reward30,31 (Supplementary Results). Using PrediXcan (Supplementary 
Methods), 36 genes were predicted to be differentially expressed in GTEx tissues or blood 
(Supplementary Table 13) with the expression of MGMT predicted to be downregulated in the 
caudate. We cautiously note that these results represent the first indications of specific pathways, 
tissues, and cell types that may mediate genetic risk for anorexia nervosa. 
Because low BMI is pathognomonic of anorexia nervosa, we investigated the extent to 
which genetic variants associated with BMI accounted for genetic correlations with metabolic 
and anthropometric traits. First, covarying for the genetic associations of BMI (Methods) led to 
a mild but statistically non-significant attenuation of the SNP-rg between anorexia nervosa and 
fasting insulin, leptin, insulin resistance, type 2 diabetes, and HDL cholesterol (Supplementary 
Tables 14-15), suggesting that anorexia nervosa shares genetic variation with these metabolic 
phenotypes that may be independent of BMI. Second, we investigated bidirectional causality 
using generalized summary data-based Mendelian randomization18. GSMR analyses indicate a 
significant bidirectional causal relationship such that anorexia nervosa risk-increasing alleles 
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may increase risk for low BMI and BMI-lowering alleles may increase the risk of anorexia 
nervosa (Supplementary Table 16). It is important to note that having only eight genome-wide 
significant loci for anorexia nervosa render this analysis marginally powered in the direction of 
anorexia nervosa to BMI, although this analysis is well powered in the direction of BMI to 
anorexia nervosa. 
Replication is challenging with GWAS of low prevalence conditions like anorexia 
nervosa, as replication samples must be sufficiently powered to detect the initial findings. We 
included all available samples in our analysis to maximize chances of reaching the GWAS 
inflection point, after which there might be a linear increase in “hits”32. The PRS leave-one-out 
analyses provide evidence of replication by demonstrating a higher burden of anorexia nervosa 
common risk variants in cases, compared with controls, across all the cohorts (Supplementary 
Fig. 16). 
 In conclusion, we report multiple genetic loci alongside promising clinical and functional 
analyses and enrichments. The increased sample size in the present GWAS has allowed us to 
characterize more fully the metabolic contribution to anorexia nervosa than our previous report10 
by revealing significant rg with metabolism related phenotypes including glycemic and 
anthropometric traits and by demonstrating that the effect is robust to correction for the effects of 
common variants significantly associated with BMI. Low BMI has traditionally been viewed as a 
consequence of the psychological features of anorexia nervosa (i.e., drive for thinness and body 
dissatisfaction). This perspective has failed to yield interventions that reliably lead to sustained 
weight gain and psychological recovery7. Fundamental metabolic dysregulation may contribute 
to the exceptional difficulty that individuals with anorexia nervosa have in maintaining a healthy 
BMI (even after therapeutic renourishment). Our results encourage consideration of both 
16 
metabolic and psychological drivers of anorexia nervosa when exploring new avenues for 
treating this frequently lethal illness.  
URLs. GCTA, http://cnsgenomics.com/software/gcta; GSMR, 
http://cnsgenomics.com/software/gsmr; LDSC, https://github.com/bulik/ldsc; MAGMA, 
http://ctg.cncr.nl/software/magma. 
 
Acknowledgements 
Grant support for ANGI, the PGC-ED, and its component groups is shown in Supplementary 
Table 17. We thank all study volunteers, study coordinators, and research staff who enabled this 
study. ANGI: The Anorexia Nervosa Genetics Initiative was an initiative of the Klarman Family 
Foundation. Additional support was offered by the National Institute of Mental Health. We 
acknowledge support from the North Carolina Translational and Clinical Sciences Institute (NC 
TraCS), the Carolina Data Warehouse, and the Foundation of Hope, Raleigh, North Carolina. 
PGC: We are deeply indebted to the investigators who +comprise the PGC, and to the hundreds 
of thousands of individuals who have shared their life experiences with PGC investigators and 
the contributing studies. We are grateful to the Children’s Hospital of Philadelphia (CHOP), the 
Price Foundation Collaborative Group (PFCG), Genetic Consortium for Anorexia Nervosa 
(GCAN), Wellcome Trust Case-Control Consortium-3 (WTCCC-3), the Lundbeck Foundation 
Initiative for Integrative Psychiatric Research (iPSYCH), the QSkin Sun and Health Study, 
Riksät (Swedish National Quality Register for Eating Disorders), the Stockholm Center for 
Eating Disorders (SCÄ), LifeGene, the UK Biobank, and all PGC-ED members for their support 
in providing individual samples used in this study. We thank SURFsara (http://www.surf.nl) for 
support in using the Lisa Compute Cluster. We thank M. Lam for Ricopili consultation. This 
17 
study also represents independent research partly funded by the English National Institute for 
Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS 
Foundation Trust and King’s College London. The views expressed are those of the author(s) 
and not necessarily those of the NHS, the NIHR or the English Department of Health and Social 
Care. High performance computing facilities were funded with capital equipment grants from the 
GSTT Charity (TR130505) and Maudsley Charity (980). Research reported in this publication 
was supported by the National Institute of Mental Health of the US National Institutes of Health 
under Award Number U01MH109514. The content is solely the responsibility of the authors and 
does not necessarily represent the official views of the US National Institutes of Health. 
 
Author contributions 
C.M.B. and P.F.S. conceived and designed the study. L.T., C.M.B., and G.B. performed overall 
study coordination. C.M.B. was lead PI of ANGI. P.F.S. was Co-Investigator of ANGI. N.G.M., 
M.L., and P.B.M. were site PIs of ANGI. H.J.W., Z.Y., J.R.I.C., C.H., J.B., H.A.G., S.Y., 
V.M.L., M.M., P.G-R. and S.E.M. performed the statistical analyses. H.J.W., Z.Y., C.H., 
J.R.I.C., H.A.G., J.B., A.H., P.G-R., P.F.S., G.B. and C.M.B. comprised the writing group. 
C.M.B. and G.B. were PGC-ED co-chairs. S.R. provided statistical consultation. A.H. assisted 
with data interpretation. A.W.B., C.M.B., J.J., M.K., K.M.K., P.L., G.M., C.N., R.P., L.T., and 
T.D.W. collected and managed the ANGI samples at sites and assisted with site-specific study 
co-ordination. A.W.B., J.M.B., H.B., S.C., K.A.H., L.J.H., C.J., A.S.K., W.K., J.M., C.M.O., 
J.F.P., N.L.P., M.S., T.W., D.C.W., and D.B.W. provided ANGI controls and extra samples. 
L.E.D provided data expertise. S.G., J.G., A.K.H., A.J., K.M.K., J.T.L., R.P., and L.P. 
contributed to the ANGI study. S.G., J.G., K.K., J.T.L., M.M., S.M., and L.P. were ANGI site 
18 
analysts. K.B.H. and K.L.P. provided additional analysis for some secondary analyses. G.W.M., 
T.D.W., A.B., P.L., and C.N. were ANGI investigators. J.J. and M.K. assisted with ANGI 
recruitment in NZ. C.M.B., G.B., and P.F.S. supervised the study. H.J.W., C.M.B., Z.Y., C.H., 
G.B., J.R.I.C., H.A.G., S.Y., J.B., P.F.S., and P.G. wrote the manuscript. PGC-ED members and 
other individuals contributed to sample acquisition and made individual data from subjects 
available: R.A.H.A., L.A. T.A., O.A.A., J.H.B., A.W.B., W.H.B., A.B., I.B., C.B., J.M.B., H.B., 
G.B., K. B., C.M.B., R.B., M.C., S.C., M.C., J.R.I.C., R.D.C., P.C., S.C., S.C., J.C., U.N.D., 
O.S.P.D, M.D, G.D., D.D., J.E.D., D.M.D., D.D., C.D., M.D., E.D.M., K.E., S.E., G.E., T.E., 
X.E., A.F., A.F., F.F., M.M.F., K.F., M.F., L.F., A.J.F., M.F., S.G., I.G., J.G., F.G., S.G., P.G., 
M.G.M., J.G., S.G., K.A.H., K.H., J.H., J.H., S.G.H., A.K.H., S.H., B.H., W.H., A.H., L.J.H., 
J.I.H., H.I., H.I., V.J., S.J., C.J., J.J., A.J., A.J., G.K., D.K., A.S.K., J.K,. L.K., A.K., M.J.H.K., 
W.K., J.L.K., M.K., A.K., K.K., Y.K., L.K., G.S.K., M.C.L, M.L., S.L., R.D.L., P.L., L.L., B.L., 
J.L., J.L., P.M., M.M., K.M., S.M., C.M., N.G.M., M.M., S.M., P.M., A.M., I.M., N.M., J.M., 
A.M.M., P.M., P.M., M.A.M., B.N., M.N., C.N., I.N., C.M.O., J.K.O., R.A.O., L.P., A.P., J.P., 
H.P., N.L.P., J.F.P., D.P., R.R., A.R., N.R., T.R., V.R., S.R., F.R., M.R., A.R., D.R., F.R., P.S., 
S.W.S., U.S., A.S., J.S., L.S., P.E.S., M.C.T.S.L., A.S., S.S., M.S., P.F.S., B.Ś., J.P.S., I.T., E.T., 
A.T., F.T., J.T., A.T., M.T., K.T., A.A.V, E.F.V., T.D.W., G.W., E.W., H.J.W., T.W., D.C.W., 
E.W., D.B.W., G.S., S.Z., and S.Z. All authors critically reviewed the manuscript.  
 
Competing interests 
The authors report the following potential competing interests. O.A.A. received a speaker’s 
honorarium from Lundbeck. G.B. received grant funding and consultancy fees in preclinical 
genetics from Eli Lilly, consultancy fees from Otsuka and has received honoraria from Illumina. 
19 
C.M.B. is a grant recipient from Shire Pharmaceuticals and served on Shire Scientific Advisory 
Board; she receives author royalties from Pearson. D.D. served as a speaker and on advisory 
boards, and has received consultancy fees for participation in research from various 
pharmaceutical industry companies including: AstraZeneca, Boehringer, Bristol Myers Squibb, 
Eli Lilly, Genesis Pharma, GlaxoSmithKline, Janssen, Lundbeck, Organon, Sanofi, UniPharma, 
and Wyeth; he has received unrestricted grants from Lilly and AstraZeneca as director of the 
Sleep Research Unit of Eginition Hospital (National and Kapodistrian University of Athens, 
Greece). J.I.H. has received grant support from Shire and Sunovion, and has received consulting 
fees from DiaMentis, Shire, and Sunovion. A.S.K. is a member of the Shire Canadian BED 
Advisory Board and is on the steering committee for the Shire B/educated Educational 
Symposium: June 15-16, 2018. J.L.K. served as an unpaid member of the scientific advisory 
board of AssurexHealth Inc. M.L. declares that, over the past 36 months, he has received lecture 
honoraria from Lundbeck and served as scientific consultant for EPID Research Oy. No other 
equity ownership, profit-sharing agreements, royalties, or patent. P.F.S. is on the Lundbeck 
advisory committee and is a Lundbeck grant recipient; he has served on the scientific advisory 
board for Pfizer, has received a consultation fee from Element Genomics, and a speaker 
reimbursement fee from Roche. J.T. has received an honorarium for participation in an EAP 
meeting and has received royalties from several books from Routledge, Wiley, and Oxford 
University press. T.W. has acted as a lecturer and scientific advisor to H. Lundbeck A/S. All 
other authors have no conflicts of interest to disclose. 
 
Additional information 
Correspondence and requests for materials should be addressed to C.M.B. or G.B. 
20 
References 
 
1. Schaumberg, K. et al. The science behind the Academy for Eating Disorders' nine truths 
about eating disorders. Eur. Eat. Disord. Rev. 25, 432-450 (2017). 
2. Keski-Rahkonen, A. & Mustelin, L. Epidemiology of eating disorders in Europe: 
prevalence, incidence, comorbidity, course, consequences, and risk factors. Curr. Opin. 
Psychiatry 29, 340-345 (2016). 
3. Hudson, J.I., Hiripi, E., Pope, H.G. & Kessler, R.C. The prevalence and correlates of 
eating disorders in the National Comorbidity Survey Replication. Biol. Psychiatry 61, 
348-358 (2007). 
4. Micali, N. et al. Lifetime and 12-month prevalence of eating disorders amongst women in 
mid-life: a population-based study of diagnoses and risk factors. BMC Med. 15, 12 
(2017). 
5. Yilmaz, Z., Hardaway, J.A. & Bulik, C.M. Genetics and epigenetics of eating disorders. 
Adv. Genomics Genet. 5, 131-150 (2015). 
6. Arcelus, J., Mitchell, A.J., Wales, J. & Nielsen, S. Mortality rates in patients with 
anorexia nervosa and other eating disorders: a meta-analysis of 36 studies. Arch. Gen. 
Psychiatry 68, 724-731 (2011). 
7. Watson, H. & Bulik, C. Update on the treatment of anorexia nervosa: review of clinical 
trials, practice guidelines and emerging interventions. Psychol. Med. 43, 2477-2500 
(2013). 
21 
8. Kirk, K.M. et al. The Anorexia Nervosa Genetics Initiative: study description and sample 
characteristics of the Australian and New Zealand arm. Aust. N. Z. J. Psychiatry 51, 583-
594 (2017). 
9. Thornton, L., Munn-Chernoff, M., Baker, J., Juréus, A. & al., e. The Anorexia Nervosa 
Genetics Initiative (ANGI): Overview and methods. Contemp. Clin. Trials 74, 61-69 
(2018). 
10. Duncan, L. et al. Significant locus and metabolic genetic correlations revealed in 
genome-wide association study of anorexia nervosa. Am. J. Psychiatry 173, 850-858 
(2017). 
11. Pickrell, J.K. et al. Detection and interpretation of shared genetic influences on 42 human 
traits. Nat. Genet. 48, 709-717 (2016). 
12. Martin, J., Taylor, M.J. & Lichtenstein, P. Assessing the evidence for shared genetic risks 
across psychiatric disorders and traits. Psychol. Med. 48, 1759-1774 (2018). 
13. Boraska, V. et al. A genome-wide association study of anorexia nervosa. Mol. Psychiatry 
19, 1085-1094 (2014). 
14. Sudlow, C. et al. UK biobank: an open access resource for identifying the causes of a 
wide range of complex diseases of middle and old age. PLoS Med. 12, e1001779 (2015). 
15. Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics 
identifies additional variants influencing complex traits. Nat. Genet. 44, 369-375 (2012). 
16. Fromer, M. et al. Gene expression elucidates functional impact of polygenic risk for 
schizophrenia. Nat. Neurosci. 19, 1442-1453 (2016). 
17. GTEx Consortium. Genetic effects on gene expression across human tissues. Nature 550, 
204-213 (2017). 
22 
18. Zhu, Z. et al. Causal associations between risk factors and common diseases inferred 
from GWAS summary data. Nat. Commun. 9, 224 (2018). 
19. Bulik-Sullivan, B.K. et al. LD Score regression distinguishes confounding from 
polygenicity in genome-wide association studies. Nat. Genet. 47, 291-295 (2015). 
20. Bulik-Sullivan, B. et al. An atlas of genetic correlations across human diseases and traits. 
Nat. Genet. 47, 1236-1241 (2015). 
21. Cederlöf, M. et al. Etiological overlap between obsessive-compulsive disorder and 
anorexia nervosa: a longitudinal cohort, multigenerational family and twin study. World 
Psychiatry 14, 333-338 (2015). 
22. Kaye, W.H., Bulik, C.M., Thornton, L., Barbarich, N. & Masters, K. Comorbidity of 
anxiety disorders with anorexia and bulimia nervosa. Am. J. Psychiatry 161, 2215-2221 
(2004). 
23. Dalle Grave, R., Calugi, S. & Marchesini, G. Compulsive exercise to control shape or 
weight in eating disorders: prevalence, associated features, and treatment outcome. 
Compr. Psychiatry 49, 346-352 (2008). 
24. Savage, J.E. et al. Genome-wide association meta-analysis in 269,867 individuals 
identifies new genetic and functional links to intelligence. Nat. Genet. 50, 912-919 
(2018). 
25. Ho, E.V., Klenotich, S.J., McMurray, M.S. & Dulawa, S.C. Activity-based anorexia 
alters the expression of BDNF transcripts in the mesocorticolimbic reward circuit. PLoS 
One 11, e0166756 (2016). 
26. Finucane, H.K. et al. Partitioning heritability by functional annotation using genome-
wide association summary statistics. Nat. Genet. 47, 1228-1235 (2015). 
23 
27. Lindblad-Toh, K. et al. A high-resolution map of human evolutionary constraint using 29 
mammals. Nature 478, 476 (2011). 
28. Bello, V. et al. The dystroglycan: nestled in an adhesome during embryonic development. 
Dev. Biol. 401, 132-142 (2015). 
29. Azevedo, F.A.C. et al. Equal numbers of neuronal and nonneuronal cells make the human 
brain an isometrically scaled-up primate brain. J. Comp. Neurol. 513, 532-541 (2009). 
30. O'Connor, E.C. et al. Accumbal D1R neurons projecting to lateral hypothalamus 
authorize feeding. Neuron 88, 553-564 (2015). 
31. Kim, J., Zhang, X., Muralidhar, S., LeBlanc, S.A. & Tonegawa, S. Basolateral to central 
amygdala neural circuits for appetitive behaviors. Neuron 93, 1464-1479.e5 (2017). 
32. Levinson, D.F. et al. Genetic studies of major depressive disorder: why are there no 
genome-wide association study findings and what can we do about it? Biol. Psychiatry 
76, 510-512 (2014). 
  
1 
 
Figure Titles and Captions 
 
Figure 1. The Manhattan plot for the primary genome-wide association meta-analysis of 
anorexia nervosa with 33 case-control samples (16,992 cases and 55,525 controls of 
European descent). The -log10(P) values for the association tests (two-tailed) are shown on the 
y-axis and the chromosomes are ordered on the x-axis. Eight genetic loci surpassed genome-wide 
significance (-log10(P) > 7.3). The lead variant is indicated by a diamond and green circles show 
the variants in linkage-disequilibrium. The blue and red colors differentiate adjacent 
chromosomes. 
 
Figure. 2. Bonferroni-significant genetic correlations (SNP-rgs) and standard errors (error 
bars) between anorexia nervosa and other phenotypes as estimated by LD score regression. 
Only traits with significant P values following Bonferroni correction are shown. Correlations 
with 447 phenotypes were tested (Bonferroni-corrected significance threshold P > 1.11 x 10-4).  
Complete results are shown in Table S10. PGC = Psychiatric Genomics Consortium, UKB = UK 
Biobank, HOMA-IR = Homeostatic model assessment - insulin resistance. 
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Table 1. Newly associated genome-wide significant loci for anorexia nervosa 
Locus Chr Basepair region Lead SNP BP P A1/A2 OR s.e. Freq Type Number 
of genes 
Nearest gene 
range left range right 
1 3 47588253 51368253 rs9821797 48718253 6.99E-15 A/T 1.17 0.02 0.12 multigenic 111 NCKIPSD 
2 11 114997256 115424956 rs6589488 115096956 6.31E-11 A/T 1.14 0.02 0.13 single-gene 1 CADM1 
3 2 53881813 54362813 rs2287348 54039813 5.62E-09 T/C 1.11 0.02 0.16 multigenic 13 ASB3, ERLEC1 
4 10 131269764 131463964 rs2008387 131448764 1.73E-08 A/G 1.08 0.01 0.33 single-gene 2 MGMT 
5 3 70670750 71074150 rs9874207 71019750 2.05E-08 C/T 1.08 0.01 0.49 single-gene 2 FOXP1 
6 1 96699455 97284455 rs10747478 96901455 3.13E-08 T/G 1.08 0.01 0.41 single-gene 2 PTBP2 
7 5 24945845 25372845 rs370838138 25081845 3.17E-08 G/C 1.08 0.01 0.56 intergenic 0 CDH10 
8 3 93968107 95059107 rs13100344 94605107 4.21E-08 T/A 1.08 0.01 0.54 intergenic 2 NSUN3 
Note. Shown are the results of the GWAS meta-analysis of anorexia nervosa (16,992 cases and 55,552 controls) which detected eight genome-wide significant 
loci. All of the eight loci are novel. Chr (chromosome) and Region (hg19) are shown for SNPs with P < 1e-05 and linkage-disequilibrium (LD) r2 > 0.1 with 
the most associated "lead" SNP, the location of which is given in BP (basepair). A1/A2 refers to Allele 1/Allele 2 and OR and s.e. are the odds ratio and 
standard error for the association between A1 and the phenotype. Freq is the frequency of A1 in controls. Number of genes was determined by genomic 
location, adult brain eQTL, regulatory chromatin interactions, and MAGMA gene-wise analysis (see Methods). Nearest gene is the nearest gene within the 
region of LD "friends" of the lead variant (LD-r2 > 0.6 +/- 500 Kb). The meta-analysis was restricted to variants with minor allele frequency (MAF) ≥ 0.01 and 
information quality (INFO) score ≥ 0.70. All loci were confirmed via forest plots based on consistent direction of effect in the majority of cohorts and via 
region plots whereby neighboring LD "friends" were required to show a similar effect. Chromosome X was analyzed but had no loci that reached genome-
wide significance. Note that although lead variants are annotated to the nearest gene, this does not mean that the gene listed is a causal gene. 
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Methods 
Samples and study design. Thirty-three datasets with 16,992 anorexia nervosa cases and 55,525 
controls were included in the primary GWAS. We included individuals from the Eating 
Disorders Working Group of the Psychiatric Genomics Consortium (PGC-ED) Freeze 110; newly 
collected samples from the Anorexia Nervosa Genetics Initiative (ANGI)8,9; archived samples 
from the Genetic Consortium for Anorexia Nervosa (GCAN)/Wellcome Trust Case Control 
Consortium-3 (WTCCC3)13; anorexia nervosa samples from UK Biobank14; and additional 
controls from Poland. Case definitions established a lifetime diagnosis of anorexia nervosa via 
hospital or register records, structured clinical interviews, or on-line questionnaires based on 
standardized criteria (DSM-III-R, DSM-IV, ICD-8, ICD-9, or ICD-10), whereas in the UK 
Biobank cases self-reported a diagnosis of anorexia nervosa. Controls were carefully matched for 
ancestry, and some, but not all control cohorts were screened for lifetime eating and/or some or 
all psychiatric disorders. Given the relative rarity of anorexia nervosa, large unscreened control 
cohorts were deemed appropriate for inclusion33.  
The cohorts are detailed in the Supplement. Ethical approvals and consent forms were 
reviewed and archived for all participating cohorts (see Supplementary Methods ANGI-DK for 
Danish methods). Summary details about ascertainment (Supplementary Table 2), the 
genotyping platforms used (Supplementary Table 3), and genotype availability (Supplementary 
Table 4) can be accessed in the Supplement.  
 
Statistical analysis. Data processing and analysis were done on the Lisa Compute Cluster hosted 
by SURFsara (http://www.surfsara.nl) and the GenomeDK high-performance computing cluster 
(http://genome.au.dk).  
2 
Meta-analysis of genome-wide association data. Quality control (QC), imputation, GWAS, and 
meta-analysis followed the standardized pipeline of the PGC, Ricopili (Rapid Imputation 
Consortium Pipeline). Ricopili versions used were 2017_Oct_11.002 and 2017_Nov_30.003. QC 
included SNP and sample QC, population stratification and ancestry outliers, and familial and 
cryptic relatedness. Further information about the Ricopili pipeline is available from the website 
(https://sites.google.com/a/broadinstitute.org/ricopili) and GitHub repository 
(https://github.com/Nealelab/ricopili/tree/master/rp_bin). Further details of the QC procedures 
can be found in the Supplementary Methods.  
 
Imputation. Imputation of SNPs and insertions-deletions was based on the 1000 Genomes Phase 
3 (http://www.internationalgenome.org) data34.  
 
GWAS. GWASs were conducted separately for each cohort using imputed variant dosages and an 
additive model. Covariates nominally associated with the phenotype in univariate analysis (P < 
0.05) and five ancestry PCs were included in GWAS (Supplementary Table 18). These analyses 
used the tests and methods programmed in the Ricopili pipeline. Genomic inflation factors (λ) of 
the final datasets indicated no evidence of inflation of the test statistics due to population 
stratification or other sources (Supplementary Table 1). The 33 cohorts were meta-analyzed with 
the Ricopili pipeline which uses an inverse-variance weighted fixed-effect model. We filtered 
our GWAS results with minor allele frequency (MAF) ≥ 0.01 and INFO score ≥ 0.70 (indicating 
“high-quality”).  
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Analysis of chrX. Several cohorts in the primary GWAS did not have X chromosome variant 
data, specifically, some GCAN-based cohorts (fre1, ukd1, usa1, gns2) and were excluded. 
Imputation was performed separately from the autosome35. ChrX variants in the 
pseudoautosomal regions were excluded prior to imputation. SNPs exceeding MAF and INFO 
score thresholds of 0.01 and 0.70 were retained and analysis was performed with PLINK v1.9 
(https://www.cog-genomics.org/plink2) and Ricopili.  
 
Female-only GWAS. A supplementary GWAS analysis was conducted on females only to 
determine the similarity of the results to the primary GWAS analysis which included both 
females and males. The cohorts that did not have chrX variants to verify sex could not be 
included (fre1, ukd1, usa1, gns2). 
 
Distance- and LD-based clumping. The GWAS results implicate genomic regions (“loci”). To 
define a locus, (1) SNPs that met the genome-wide significant threshold of P < 5 × 10-8 were 
identified; (2) clumping was used to convert significant SNPs to regions. The SNP with the 
smallest P value in a genomic window was kept as the index SNP and SNPs in high linkage 
disequilibrium (LD) with the index SNP defined the left and right end of the region (SNPs with 
P < 0.0001 and r 2 > 0.1 within 3 Mb windows); (3) partially or wholly overlapping clumps 
within 50 Kb were identified and merged into one region; (4) only loci with additional evidence 
of association from variants in high LD as depicted by regional plots were retained; further, 
forest plots needed to confirm the associations based on the majority of cohorts; and (5) 
conditional analyses were conducted to identify SNPs with associations independent of the top 
SNP within the genomic chunk of interest.  
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Annotation. Genome-wide significant loci were annotated with RegionAnnotator 
(https://github.com/ivankosmos/RegionAnnotator) to identify known protein-coding genes 
within loci (Supplementary Table 6).  
 
Conditional and joint analysis. Conditional and joint analysis was conducted using GCTA-
COJO15. GCTA-COJO investigates every locus with a joint combination of independent markers 
via a genome-wide SNP selection procedure. It takes into account the LD correlations between 
SNPs and runs a conditional and joint analysis on the basis of conditional P values. After a 
model optimizing process, the joint effects of all selected SNPs are calculated. The largest 
subsample from our GWAS (sedk) was used to approximate the underlying LD structure of the 
investigated lead SNPs. The conditional regression was performed in a stepwise manner using 
the GCTA software36. We analyzed SNPs that had a P < 5 × 10-8 (Supplementary Table 5).  
 
Multi-trait-based conditional and joint analysis. To separate marginal effects from conditional 
effects (i.e., the effect of a risk factor on an outcome controlling for the effect of another risk 
factor), we performed a multi-trait-based conditional and joint analysis (GCTA-mtCOJO)18 using 
an extension of the GCTA software36 (Supplementary Table 8). This method uses summary-level 
data to perform the conditional analysis. We conditioned the results of our anorexia nervosa 
GWAS on GWAS results for education years37, type 2 diabetes38, HDL cholesterol39, BMI 
(Hübel, Gaspar, Coleman, Hanscombe, Purves…Breen, unpublished report), schizophrenia40, 
and neuroticism41. We again used the individual-level genotype data from our largest cohort 
(sedk) to approximate the underlying LD structure. As a first step, the method performs a 
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generalized summary data-based Mendelian randomization (GSMR) analysis to test for causal 
association between the outcome (i.e., anorexia nervosa) and the risk factor (e.g., schizophrenia). 
We removed potentially pleiotropic SNPs from this analysis by the heterogeneity in dependent 
instruments (HEIDI) outlier method18. Pleiotropy is the phenomenon when a single locus directly 
affects several phenotypes. The power of the HEIDI-outlier method is dependent on sample size 
of the GWAS. Pleiotropic SNPs are defined as the SNPs that show an effect on the outcome that 
significantly diverges from that expected under a causal model. Second, the GCTA-mtCOJO 
method calculates the genetic correlation between the exposure and the outcome using linkage 
disequilibrium score regression (LDSC) to adjust for genetic overlap19,20. It also uses the 
intercept of the bivariate LDSC to account for potential sample overlap19,20. As a result, GCTA-
mtCOJO calculates conditional betas, conditional standard errors, and conditional P values. 
Subsequently, we clumped the conditional GWAS results using the standard PLINK v1.942 
algorithm (SNPs with P < 0.0001 and r2 > 0.1 within 3 Mb windows) to investigate if any of the 
genome-wide significant loci showed dependency on genetic variation associated with other 
phenotypes. As stated in Zhu et al.18, the GCTA-mtCOJO analysis requires the estimates of bxy 
of the covariate risk factors on the target risk factor and disease, rg of the covariate risk factors, 
heritability (h2snp) for the covariate risk factors, and the sampling covariance between SNP 
effects estimated from potentially overlapping samples.  
 
eQTL and Hi-C interactions. Although GWAS findings are informative genome-wide, 
identifying strong hypotheses about their connections to specific genes is not straightforward. 
The lack of direct connections to genes constrains subsequent experimental modeling and efforts 
to develop improved therapeutics. Genomic location is often used to connect significant SNPs to 
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genes, but this is problematic because GWAS loci usually contain many correlated and highly 
significant SNP associations over hundreds of Kb. Moreover, the three-dimensional (3D) 
arrangement of chromosomes in cell nuclei enables regulatory interactions between genomic 
regions located far apart43. Chromosome conformation capture methods like Hi-C enable 
identification of 3D interactions in vivo44,45 and can clarify GWAS findings. For example, an 
intergenic region associated with multiple cancers was shown to be an enhancer for MYC via a 
long-range chromatin loop46,47, and intronic FTO variants are robustly associated with body mass 
but influence expression of distal genes via long-range interactions48. The Nature paper of Won 
et al.49 used Hi-C to assess the 3D chromatin interactome in fetal brain, and asserted connections 
of some schizophrenia associations to specific genes.  
To gain further understanding of 3D chromatin organization of the brain and to evaluate 
disease relevance, we applied “easy Hi-C”50 to postmortem samples (N = 3 adult temporal 
cortex). Library quality and yield from eHi-C are comparable to conventional Hi-C but requires 
much less starting material. Please refer to the following pre-print for details on methodology, 
data processing, quality control and statistical models used for these analyses51. We generated 
sufficient reads to enable a kilobase resolution map of the chromatin interactome from adult 
human brain. To our knowledge, these are the deepest Hi-C data on any human tissue (excluding 
cell lines) as they generated 22.5X as many cis-contacts as for the next largest datasets (DLPFC 
and hippocampus). We generated tissue RNA-seq, total-stranded RNA-seq, ChIP-seq (H3K27ac, 
H3K4me3, and CTCF), and open chromatin data (ATAC-seq) for adult brain to help interpret the 
eHi-C results. We also integrated brain expression and eQTL data from GTEx to aid these 
analyses. The Hi-C analysis is unbiased in that all chromatin interactions that pass a confidence 
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threshold are considered when evaluating the associations between SNPs and genes (i.e., it is not 
a capture experiment where only “candidate” SNP-to-gene associations are evaluated). 
Similar to the work by Won et al.49, we used Hi-C data generated from human adult brain 
to identify genes implicated by three-dimensional functional interactomics (Supplementary Figs. 
5 a-h). These Hi-C data (N = 3, anterior temporal cortex) contain more than 103K high-
confidence, regulatory chromatin interactions51. These interactions capture the physical 
proximity of two regions of the genome in brain nuclei (“anchors”, 10 Kb resolution) although 
they are separated by 20 Kb to 2 Mb in genomic distance. We focused on the regulatory subset 
of E-P or P-P (E = enhancer, P = promoter) chromatin interactions (with P defined by location of 
an open chromatin anchor near the transcription start site of an adult brain-expressed transcript 
and E defined by overlap with open chromatin in adult brain plus either H3K27ac or H3K4me3 
histone marks). The presence of a regulatory chromatin interaction from a GWAS locus to a gene 
provides a strong hypothesis about SNP-to-gene regulatory functional interactions. 
 
SNP-based heritability estimation. LDSC software (https://github.com/bulik/ldsc) and method 
were used to estimate SNP-based heritabilities for each cohort and overall19,20. We used 
precomputed LD scores based on the 1000 Genomes Project European ancestry samples34 
directly downloaded from https://github.com/bulik/ldsc. The liability scale estimate assumed a 
population prevalence of 0.9%-4% for anorexia nervosa2,3.  
 
Within-trait prediction: polygenic risk scoring. Polygenic leave-one-dataset-out analysis, using 
PRSice v2.1.352, was conducted in the first instance to identify any extreme outlying datasets. In 
addition, it enabled the evaluation of the association between anorexia nervosa polygenic risk 
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score (PRS) and anorexia nervosa risk in an independent cohort as a means of replication of the 
GWAS results. We derived a PRS for anorexia nervosa from the meta-analysis of all datasets 
except for the target cohort, then applied the PRS to the target cohort to predict affected status 
(Supplementary Fig. 16). Logistic regression was performed, including as covariates the first five 
ancestry components and any other PCs significantly associated with the phenotype in the target 
cohort, and the target cohort was split into deciles based on anorexia nervosa PRS, with decile 1 
comprised of those with the lowest anorexia nervosa PRS serving as the referent.  
 
Anorexia nervosa subtype analysis. PRS analyses were conducted with anorexia nervosa 
subgroups to investigate prediction of case status across the subtypes. For this, we split the 
anorexia nervosa cases to two groups based on whether binge eating was present. First, GWAS 
meta-analyses were conducted for (a) anorexia nervosa with binge eating vs controls (2,381 
cases and 10,249 controls; k = 3 datasets: aunz, chop, usa2) and (b) anorexia nervosa with no 
binge eating vs controls (2,262 cases and 10,254 controls; k = 3 datasets: aunz, chop, usa2). 
Controls were randomly split between analyses to maintain independence (Supplementary Fig. 
6). Genetic correlation analysis using LDSC19,20 was conducted to examine the potential genetic 
overlap of the two anorexia nervosa subtypes (Supplementary Table 9). Second, using PRSice52, 
we calculated PRS for each anorexia nervosa subtype separately in the three target cohorts for 
which anorexia nervosa subtype data were available. Finally, mean PRS scores were estimated 
for each subtype by cohort after accounting for covariates in R. Subtype phenotyping is 
described in the Supplementary Methods.  
 
9 
Males. In order to assess whether sex-specific differences in anorexia nervosa genetic risk load 
exist, we calculated PRS, using PRSice52, from a GWAS meta-analysis performed on females 
only (14,898 cases and 27,545 controls) and applied it to a male-only target cohort (447 cases 
and 20,347 controls) to predict affected status.  
 
Cross-trait analysis: genetic correlations. Common variant-based genetic correlation (SNP-rg) 
measures the extent to which two traits or disorders share common genetic variation. SNP-rg 
between anorexia nervosa and 447 traits (422 from an internally curated dataset and 25 from 
LDHub53) were tested using GWAS summary statistics via an analytical extension of LDSC19,20. 
The sources of the summary statistics files (PMID, DOI, or unpublished results) used in the 
LDSC are provided in Supplementary Table 10. When there were multiple summary statistics 
files available for a trait, significant SNP-rg reported in the main text were chosen based on the 
largest sample size and/or matching ancestry with our sample (i.e., European ancestry). 
Genetic correlations with anorexia nervosa corrected for BMI were carried out to 
investigate whether the observed genetic correlations between anorexia nervosa and metabolic 
phenotypes were attributable to BMI or partially independent. We used GCTA-mtCOJO18 to 
perform a GWAS analysis for anorexia nervosa conditioning on BMI using BMI summary data 
from our UK Biobank analysis (described in the next section) to derive anorexia nervosa GWAS 
summary statistics corrected for  the common variants genetic component of BMI 
(Supplementary Tables 14 and 15).  
 
GWAS of related traits in UK Biobank. Several GWAS analyses were carried out for traits in UK 
Biobank to allow us to investigate body composition genetics in healthy individuals without a 
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psychiatric disorder, a weight-altering disorder, or who were taking weight-altering medication. 
We also used UK Biobank to carry out GWAS of physical activity level, anxiety, and 
neuroticism. For details see the Supplementary Methods. 
 
Generalized summary data-based Mendelian randomization (GSMR). We performed two 
bidirectional GSMR analyses18 to test for the causal association between first, BMI and anorexia 
nervosa, and second, Type 2 diabetes and anorexia nervosa, using an extension of the GCTA 
software36 (Supplementary Table 16). We used the individual-level genotype data from our 
largest cohort (sedk) to approximate the underlying LD structure. We removed potentially 
pleiotropic SNPs from this analysis by the HEIDI outlier method18. Pleiotropic SNPs are defined 
as the SNPs which show an effect on the outcome that significantly diverges from the one 
expected under a causal model. The method uses the intercept of the bivariate LD score 
regression to account for potential sample overlap19,20. As a rule of thumb GSMR requires 
GWAS to have at least ten genome-wide significant hits. We lowered the threshold for this 
requirement to eight SNPs in our analyses of anorexia nervosa as an exposure and BMI or Type 
2 diabetes as an outcome. Results, therefore, should be interpreted cautiously. We, furthermore, 
investigated bidirectional conditional effects between BMI or Type 2 diabetes and anorexia 
nervosa. We used GCTA-mtCOJO to perform a GWAS analysis for anorexia nervosa 
conditioning on (1) BMI using summary data from our UK Biobank analysis and (2) Type 2 
diabetes using summary data38. Our anorexia nervosa GWAS and the BMI and Type 2 diabetes 
GWASs are based on independent samples. For BMI, we also re-ran the GSMR analysis using 
the BMI-adjusted anorexia nervosa GWAS summary data from the GCTA-mtCOJO analysis.  
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Gene-wise analysis. MAGMA v1.0654 was used to perform a gene-wise test of association with 
anorexia nervosa based on GWAS summary statistics. MAGMA generates gene-based P values 
by combining SNP-based P values within a gene while accounting for LD. In order to include 
regulatory regions, SNPs are mapped to genes within a 35 kb upstream and 10 kb downstream 
window, and the gene P value is obtained using the “multi=snp-wise” model, which aggregates 
mean and top SNP association models. We tested 19,846 ENSEMBL genes, including the X 
chromosome (Supplementary Table 11). As reference panel for the underlying LD structure we 
used 1000 Genomes European data phase 334.  
 
Pathway analysis. MAGMA v1.0654 was used to perform a competitive pathway analysis, testing 
whether genes associated with anorexia nervosa were more enriched in a given pathway than all 
other pathways. The analysis included chrX. Biological pathways were defined using gene 
ontology pathways and canonical pathways from MSigDB v6.155, and psychiatric pathways 
mined from the literature. A total 7,268 pathways were tested (Supplementary Table 12).  
 
Partitioned heritability. Partitioned heritability was investigated using stratified LDSC26 which 
estimates the per-SNP contribution to overall SNP-heritability (SNP-h2) across various 
functional annotation categories of the genome (Supplementary Fig. 7). It accounts for linked 
markers and uses a ‘full baseline model’ of 24 annotations that are not specific to any cell type. 
We excluded the MHC region in our analysis. SNP-h2 can be partitioned in two different ways: a 
non-cell type-specific and a cell type-specific manner. Partitioned heritability analysis was used 
to test for cell type-specific enrichment in the GWAS of anorexia nervosa among 10 cell type 
groups; adrenal and pancreas, cardiovascular, central nervous system (CNS), connective and 
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bone, gastrointestinal, immune and hematopoietic, kidney, liver, skeletal muscle, and other 
tissue, which includes adipose tissue (Supplementary Fig. 8).  
 
Gene expression. We conducted a series of gene expression analyses as detailed in the 
Supplementary Methods.  
 
Reporting summary 
 
Further information on research design is available in the Life Science Reporting Summary 
linked to this article. 
 
Data availability 
 
The Psychiatric Genomics Consortium’s (PGC) policy is to make genome-wide summary results 
public. Genome-wide summary statistics for the meta-analysis are freely downloadable from 
PGCs download website (http://www.med.unc.edu/pgc/results-and-downloads). Individual-level 
data are deposited in dbGaP (http://www.ncbi.nlm.nih.gov/gap) for ANGI-ANZ/SE/US 
(accession number phs001541.v1.p1) and CHOP/PFCG (accession number phs000679.v1.p1). 
ANGI-DK individual-level data are not available in dbGaP owing to Danish laws, but are 
available via collaboration with PIs. GCAN/WTCCC3 individual-level data are deposited in 
EGA (https://www.ebi.ac.uk/ega) (accession number EGAS00001000913) with the exception of 
Netherlands and US/Canada, which are available via collaboration with PIs. UK Biobank 
13 
individual-level data can be applied for on the UK Biobank website 
(http://www.ukbiobank.ac.uk/register-apply). 
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Supplementary Figure 2a-h legend. Forest plots of GWAS meta-analysis results for all genome-wide significant SNPs (P < 
5 × 10-8). The overall sample size is 16,992 cases and 55,525 controls. For specific cohort sample sizes, see 
Supplementary Table 1. Two SNPs were located in regions that overlapped (index SNPs of rs9821797 and rs73088112), 
therefore we refer to only one of these (rs9821797) in the main manuscript. The red vertical line is the reference line of no 
effect. The center values are ln(OR) estimates from logistic regression association analyses and the error bars show the 
95% confidence interval.   
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−0.055
−0.0721
−0.00894
−0.00773
−0.074
0.0288
0.215
−0.0752
−0.0642
−0.276
0.0184
−0.0327
−0.324
−0.17
−0.287
−0.245
−0.193
−0.0146
−0.0274
0.132
0.0282
−0.104
9.7
STDerr
0.041
0.0684
0.176
0.132
0.083
0.24
0.115
0.155
0.0443
0.233
0.0771
0.15
0.118
0.076
0.168
0.159
0.155
0.161
0.175
0.152
0.16
0.161
0.141
0.143
0.0978
0.147
0.166
0.145
0.163
0.0768
0.204
0.161
0.16
0.0179
−0.5 0 0.5
ln(OR), 95% CI
rs2008387
aunz
chop
fin1
fre1
gns2
itgr
net1
poco
sedk
spa1
ukbb
ukd1
usa1
usa2
w10
w11
w12
w13
w14
w15
w16
w17
w18
w19
w1to6
w20
w21
w22
w23
w24
w7
w8
w9
Meta−analysis
ngt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
G/A
+++++−+−+++++−+−++++++++++−−++++−
info
0.93
0.93
1.01
0.82
0.89
0.94
0.93
0.91
0.93
0.77
0.93
0.97
0.93
0.94
0.99
0.92
0.95
0.92
0.99
0.96
0.97
0.93
0.99
1.02
0.95
0.94
0.93
1.02
1.00
0.95
0.99
1.02
0.98
0.94
p_value
0.0565
0.0522
0.182
0.0967
0.0999
0.397
0.569
0.414
0.0226
0.829
0.153
0.416
0.0052
0.969
0.413
0.586
0.0747
0.0199
0.0276
0.632
0.307
0.00996
0.0714
0.956
0.693
0.745
0.383
0.779
0.241
0.681
0.0175
0.803
0.952
1.72e−08
10:131448764
het_P:
f_ca(n)
0.650(2536)
0.638(1032)
0.556(130)
0.653(293)
0.653(657)
0.677(144)
0.680(348)
0.693(239)
0.645(4105)
0.677(184)
0.652(768)
0.653(242)
0.622(418)
0.652(1304)
0.643(156)
0.692(164)
0.645(176)
0.620(181)
0.617(169)
0.648(185)
0.658(174)
0.635(158)
0.630(245)
0.672(211)
0.666(357)
0.675(200)
0.706(161)
0.660(211)
0.656(164)
0.663(1241)
0.598(97)
0.682(162)
0.667(180)
0.651(16992)
0.358
f_co(n)
0.663(15624)
0.668(3568)
0.600(503)
0.687(990)
0.677(2263)
0.642(129)
0.698(1337)
0.661(604)
0.661(3793)
0.676(156)
0.670(3065)
0.674(957)
0.674(750)
0.654(1307)
0.664(714)
0.677(754)
0.696(785)
0.679(789)
0.681(761)
0.665(818)
0.681(800)
0.706(761)
0.675(852)
0.671(851)
0.674(4828)
0.683(802)
0.676(801)
0.653(845)
0.685(957)
0.668(1447)
0.678(831)
0.688(1062)
0.661(1021)
0.670(55525)
het_I:
ln(OR)
−0.0633
−0.109
−0.19
−0.189
−0.117
0.164
−0.0548
0.104
−0.08
−0.0427
−0.0895
−0.0893
−0.265
0.0024
−0.109
0.0751
−0.229
−0.297
−0.279
−0.06
−0.132
−0.357
−0.195
−0.00652
−0.0332
−0.0402
0.122
0.0319
−0.15
−0.0245
−0.38
−0.0317
0.00747
−0.0815
6.7
STDerr
0.0332
0.056
0.142
0.114
0.0708
0.193
0.0961
0.128
0.0351
0.197
0.0625
0.11
0.0949
0.0606
0.133
0.138
0.128
0.128
0.127
0.125
0.129
0.139
0.108
0.116
0.0844
0.124
0.14
0.114
0.128
0.0595
0.16
0.127
0.124
0.0145
−0.6 −0.4 −0.2 0 0.2 0.4
ln(OR), 95% CI
rs9874207
aunz
chop
fin1
fre1
gns2
itgr
net1
poco
sedk
spa1
ukbb
ukd1
usa1
usa2
w10
w11
w12
w13
w14
w15
w16
w17
w18
w19
w1to6
w20
w21
w22
w23
w24
w7
w8
w9
Meta−analysis
ngt
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
T/C
−−++−−−−−−−+−+−−+−−+++++−+−−−−++−
info
0.79
0.87
0.97
0.84
0.88
0.89
0.91
0.86
0.82
0.85
1.01
0.87
0.86
0.77
0.87
0.86
0.88
0.87
0.86
0.87
0.83
0.88
0.86
0.86
0.85
0.83
0.85
0.88
0.85
0.85
0.84
0.81
0.86
0.84
p_value
0.00971
0.0004
0.265
0.723
0.564
0.972
0.178
0.0313
0.0197
0.723
0.0246
0.979
0.00122
0.335
0.0727
0.804
0.535
0.233
0.683
0.891
0.599
0.889
0.748
0.716
0.00504
0.998
0.346
0.285
0.846
0.0416
0.951
0.616
0.895
2.05e−08
3:71019750
het_P:
f_ca(n)
0.483(2536)
0.472(1032)
0.554(130)
0.488(293)
0.486(657)
0.469(144)
0.472(348)
0.452(239)
0.512(4105)
0.470(184)
0.467(768)
0.485(242)
0.450(418)
0.488(1304)
0.460(156)
0.485(164)
0.506(176)
0.483(181)
0.500(169)
0.519(185)
0.542(174)
0.528(158)
0.522(245)
0.525(211)
0.460(357)
0.538(200)
0.500(161)
0.489(211)
0.513(164)
0.495(1241)
0.512(97)
0.520(162)
0.512(180)
0.493(16992)
0.212
f_co(n)
0.500(15624)
0.512(3568)
0.522(503)
0.485(990)
0.492(2263)
0.466(129)
0.500(1337)
0.497(604)
0.532(3793)
0.493(156)
0.499(3065)
0.486(957)
0.514(750)
0.477(1307)
0.517(714)
0.494(754)
0.491(785)
0.520(789)
0.512(761)
0.518(818)
0.527(800)
0.524(761)
0.517(852)
0.514(851)
0.511(4828)
0.536(802)
0.524(801)
0.515(845)
0.517(957)
0.520(1447)
0.507(831)
0.510(1062)
0.517(1021)
0.507(55525)
het_I:
ln(OR)
−0.0889
−0.197
0.16
0.0376
−0.0389
−0.00662
−0.123
−0.266
−0.0833
−0.0621
−0.128
0.003
−0.307
0.0615
−0.243
−0.0329
0.0786
−0.151
−0.0532
0.0173
0.0693
0.0187
0.036
0.0429
−0.237
0.0003
−0.126
−0.125
−0.0254
−0.122
0.0103
0.0669
−0.0163
−0.0813
16.0
STDerr
0.0344
0.0557
0.144
0.106
0.0676
0.186
0.091
0.124
0.0357
0.175
0.057
0.11
0.0951
0.0638
0.135
0.132
0.127
0.126
0.13
0.126
0.132
0.135
0.112
0.118
0.0845
0.123
0.134
0.117
0.131
0.0597
0.169
0.133
0.124
0.0145
−0.4 −0.2 0 0.2 0.4
ln(OR), 95% CI
rs10747478
aunz
chop
fin1
fre1
gns2
itgr
net1
poco
sedk
spa1
ukbb
ukd1
usa1
usa2
w10
w11
w12
w13
w14
w15
w16
w17
w18
w19
w1to6
w20
w21
w22
w23
w24
w7
w8
w9
Meta−analysis
ngt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
T/G
+++−+++−++++++−−++++++++++−+−+−++
info
0.97
1.00
0.96
0.98
0.96
1.04
0.96
0.98
1.00
0.93
0.96
1.01
0.93
0.94
0.94
0.87
0.94
1.02
0.96
0.99
0.96
0.98
1.04
0.99
0.93
0.99
0.95
0.99
1.00
0.95
0.92
0.99
1.00
0.97
p_value
0.0241
0.198
0.136
0.748
0.111
0.87
0.344
0.941
0.151
0.291
0.318
0.146
0.286
0.811
0.746
0.98
0.435
0.0445
0.624
0.988
0.00441
0.149
0.683
0.0667
0.000906
0.0261
0.812
0.968
0.049
0.0856
0.087
0.0203
0.308
3.13e−08
1:96901455
het_P:
f_ca(n)
0.421(2536)
0.438(1032)
0.411(130)
0.415(293)
0.455(657)
0.513(144)
0.437(348)
0.439(239)
0.430(4105)
0.419(184)
0.419(768)
0.417(242)
0.434(418)
0.421(1304)
0.418(156)
0.441(164)
0.438(176)
0.465(181)
0.440(169)
0.439(185)
0.482(174)
0.443(158)
0.407(245)
0.474(211)
0.479(357)
0.475(200)
0.416(161)
0.415(211)
0.372(164)
0.421(1241)
0.367(97)
0.473(162)
0.449(180)
0.431(16992)
0.149
f_co(n)
0.401(15624)
0.427(3568)
0.366(503)
0.427(990)
0.429(2263)
0.500(129)
0.420(1337)
0.447(604)
0.421(3793)
0.387(156)
0.405(3065)
0.376(957)
0.410(750)
0.419(1307)
0.424(714)
0.440(754)
0.415(785)
0.408(789)
0.424(761)
0.430(818)
0.404(800)
0.386(761)
0.397(852)
0.424(851)
0.420(4828)
0.411(802)
0.420(801)
0.412(845)
0.427(957)
0.399(1447)
0.430(831)
0.406(1062)
0.421(1021)
0.412(55525)
het_I:
ln(OR)
0.0707
0.0679
0.222
−0.0319
0.104
0.0283
0.084
−0.00854
0.0469
0.186
0.0591
0.152
0.0983
0.014
−0.0431
−0.00341
0.0973
0.236
0.0614
0.0018
0.352
0.186
0.042
0.203
0.269
0.254
−0.0305
0.00449
−0.246
0.0987
−0.282
0.281
0.118
0.0757
20.6
STDerr
0.0314
0.0527
0.149
0.0992
0.0653
0.172
0.0888
0.115
0.0327
0.176
0.0592
0.104
0.0921
0.0585
0.133
0.133
0.124
0.118
0.125
0.119
0.124
0.129
0.103
0.111
0.0811
0.114
0.128
0.111
0.125
0.0574
0.165
0.121
0.116
0.0137
−0.6 −0.4 −0.2 0 0.2 0.4
ln(OR), 95% CI
rs370838138
aunz
chop
fin1
fre1
gns2
itgr
net1
poco
sedk
spa1
ukbb
ukd1
usa1
usa2
w10
w11
w12
w13
w14
w15
w16
w17
w18
w19
w1to6
w20
w21
w22
w23
w24
w7
w8
w9
Meta−analysis
ngt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
G/C
−−−−−−−−−+−−−+−+−+−−−−−−+++−−−−−−
info
0.99
0.99
0.99
0.98
0.95
0.97
1.02
0.92
1.00
0.93
1.01
1.04
0.96
0.95
1.03
0.98
0.97
1.00
1.02
0.95
0.96
0.96
0.98
0.99
0.96
0.93
1.04
1.03
0.93
0.96
0.93
1.00
0.98
0.98
p_value
0.164
0.000315
0.429
0.455
0.0855
0.982
0.46
0.527
0.0499
0.233
0.0125
0.11
0.502
0.793
0.0683
0.905
0.0919
0.563
0.0676
0.716
0.174
0.841
0.902
0.131
0.702
0.816
0.984
0.0724
0.278
0.284
0.879
0.592
0.0358
3.17e−08
5:25081845
het_P:
f_ca(n)
0.574(2536)
0.607(1032)
0.535(130)
0.617(293)
0.590(657)
0.625(144)
0.597(348)
0.546(239)
0.563(4105)
0.609(184)
0.592(768)
0.578(242)
0.588(418)
0.586(1304)
0.618(156)
0.568(164)
0.614(176)
0.549(181)
0.622(169)
0.572(185)
0.614(174)
0.576(158)
0.564(245)
0.614(211)
0.571(357)
0.586(200)
0.591(161)
0.617(211)
0.595(164)
0.589(1241)
0.555(97)
0.577(162)
0.633(180)
0.582(16992)
0.637
f_co(n)
0.560(15624)
0.563(3568)
0.504(503)
0.589(990)
0.563(2263)
0.629(129)
0.576(1337)
0.520(604)
0.548(3793)
0.664(156)
0.555(3065)
0.535(957)
0.567(750)
0.592(1307)
0.559(714)
0.575(754)
0.565(785)
0.567(789)
0.570(761)
0.562(818)
0.573(800)
0.559(761)
0.563(852)
0.575(851)
0.579(4828)
0.591(802)
0.590(801)
0.569(845)
0.564(957)
0.574(1447)
0.558(831)
0.562(1062)
0.572(1021)
0.564(55525)
het_I:
ln(OR)
0.043
0.194
0.113
0.0755
0.113
0.00409
0.0649
0.0744
0.0638
−0.211
0.145
0.162
0.0605
−0.0154
0.233
−0.0149
0.209
−0.0685
0.226
0.0437
0.172
0.0257
0.013
0.171
−0.0306
−0.0274
−0.0024
0.199
0.138
0.0607
0.0245
0.0649
0.253
0.0753
0.0
STDerr
0.0309
0.0539
0.143
0.101
0.066
0.183
0.0878
0.117
0.0325
0.177
0.0579
0.102
0.0901
0.0586
0.128
0.125
0.124
0.118
0.124
0.12
0.126
0.128
0.105
0.113
0.0798
0.118
0.123
0.111
0.127
0.0567
0.16
0.121
0.12
0.0136
−0.4 −0.2 0 0.2 0.4
ln(OR), 95% CI
rs13100344
aunz
chop
fin1
fre1
gns2
itgr
net1
poco
sedk
spa1
ukbb
ukd1
usa1
usa2
w10
w11
w12
w13
w14
w15
w16
w17
w18
w19
w1to6
w20
w21
w22
w23
w24
w7
w8
w9
Meta−analysis
ngt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
T/A
−−−−−−−−−−−−−−−++++−−+++−−+−−−−−−
info
0.98
0.95
1.03
0.93
0.88
0.94
1.00
0.91
0.99
0.86
0.97
0.98
0.97
0.97
0.99
0.96
0.92
1.02
1.00
0.98
0.97
0.98
0.92
0.97
0.98
0.98
0.98
1.00
0.97
0.99
0.99
0.86
0.86
0.96
p_value
0.000439
0.489
0.388
0.921
0.829
0.162
0.145
0.135
0.0447
0.608
0.0162
0.131
0.0291
0.021
0.0194
0.539
0.57
0.184
0.404
0.104
0.63
0.49
0.752
0.0935
0.0646
0.0342
0.24
0.284
0.955
0.8
0.997
0.534
0.268
4.21e−08
3:94605107
het_P:
f_ca(n)
0.564(2536)
0.545(1032)
0.482(130)
0.535(293)
0.530(657)
0.626(144)
0.534(348)
0.581(239)
0.530(4105)
0.550(184)
0.581(768)
0.585(242)
0.580(418)
0.567(1304)
0.617(156)
0.535(164)
0.517(176)
0.513(181)
0.528(169)
0.582(185)
0.572(174)
0.521(158)
0.526(245)
0.531(211)
0.586(357)
0.574(200)
0.521(161)
0.561(211)
0.535(164)
0.556(1241)
0.557(97)
0.555(162)
0.566(180)
0.551(16992)
0.175
f_co(n)
0.536(15624)
0.541(3568)
0.448(503)
0.524(990)
0.526(2263)
0.580(129)
0.505(1337)
0.535(604)
0.513(3793)
0.541(156)
0.547(3065)
0.549(957)
0.528(750)
0.538(1307)
0.547(714)
0.554(754)
0.534(785)
0.553(789)
0.552(761)
0.535(818)
0.553(800)
0.543(761)
0.532(852)
0.571(851)
0.551(4828)
0.514(802)
0.553(801)
0.535(845)
0.541(957)
0.553(1447)
0.557(831)
0.539(1062)
0.536(1021)
0.537(55525)
het_I:
ln(OR)
0.109
0.037
0.122
0.01
0.0146
0.263
0.127
0.179
0.0653
0.0901
0.141
0.158
0.196
0.132
0.305
−0.0777
−0.0702
−0.157
−0.101
0.194
0.0594
−0.0873
−0.0343
−0.188
0.148
0.243
−0.147
0.118
0.00698
0.0141
0.0006
0.0807
0.139
0.0746
18.6
STDerr
0.0311
0.0535
0.141
0.101
0.0677
0.188
0.0871
0.12
0.0325
0.176
0.0588
0.105
0.0898
0.0571
0.13
0.126
0.124
0.118
0.121
0.119
0.123
0.127
0.108
0.112
0.08
0.115
0.125
0.11
0.124
0.0554
0.156
0.13
0.125
0.0136
−0.4 −0.2 0 0.2 0.4 0.6
ln(OR), 95% CI
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p = 5.0e−08
filter: p < 0.03
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Supplementary Figure 4. A random-effects meta-analysis of the association between rs4622308 and 
anorexia nervosa. Previously, the first freeze of the PGC-ED revealed that this SNP was genome-wide 
significant (Duncan et al., 2017). In the present study, this SNP was not genome-wide significant in the 
primary GWAS meta-analysis using a fixed-effects model, and in a subsequent random effects meta-
analysis as shown in this figure was also non-significant and showed evidence of heterogeneity (odds 
ratio [OR] = 1.06, 95% CI = 1.01-1.11, Ptwo-tailed = 0.0002, I2 = 53.76). The percentages refer to the 
weight assigned to each cohort. The figures on the right are the percentage weight assigned to each 
cohort, the center values are the OR, and the error bar is the 95% confidence interval. The vertical line 
is the reference line of no effect. The sample size is 16,992 cases and 55,525 controls. 
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Supplementary Figure 5a-h legend. Hi-C and eQTL analyses. These figures were generated using the WashU 
EpiGenome browser (http://epigenomegateway.wustl.edu/browser). Yellow shaded regions show the “clumps” associated 
with AN. The top track shows GENCODE v19 gene models. The "public clumps" track shows psychiatric GWA regions 
including AN GWAS. The "Hi-C Ad cortex" track shows "compartment A/B", "FIRES" (frequently interacting regions), 
"superFIRES" (local aggregates of FIREs), and topologically associated domain boundaries (TADs). The "Hi-C Ad loops 
E-P narrow" contains arcs that show the positions of high confidence chromatin interactions in adult brain (10 Kb 
resolution) between enhancers and/or promoters (according to ChIP-seq and brain-expressed TSS data) with a 
Bonferroni P < 0.001. The "eQTL Ad brain" track shows cis eQTL information from GTEx for all available brain tissues. 
The "ATAC Ad ctx pool30" track shows open chromatin data for 30 adult controls. The next three tracks show brain 
epigenomic marks from ChIP-seq in adult brain cortex (H3K27ac, H3K4me3, and CTCF). We selected eQTL SNP-gene 
pairs from CommonMind frontal cortex, GTEx in any brain region (q < 0.05), or in fetal cortex. Significant eQTL 
connections were identified by nominal P < 0.05 as supplied by CMC and GTEx and significant chromatin interactions 
were identified with a stringent Bonferroni correction for multiple testing, and only considered 10 Kb bin pairs with P value 
< 2.31 × 10-11 (0.001/43,222,677 tests). The chromatin interaction tests came from Fit-Hi-C with default parameters 
applied and FastHiC. All tests were two-tailed. 
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Supplementary Figure 6. Mean polygenic risk scores (PRS) according to anorexia nervosa subtype (+/- binge eating). In 
the datasets with available subtype data—aunz (1,417 cases with binge eating, 997 cases without binge eating), chop 
(358 cases with binge eating, 634 cases without binge eating), and usa2 (606 cases with binge eating, 631 cases without 
binge eating)— AN PRS was computed for each individual. AN PRS was derived from the primary GWAS meta-analysis 
summary statistics and adjusted for the principal components used in the main GWAS. Individual PRS were then 
aggregated into subtype group means. The center values show mean PRS and the error bars show the 95% confidence 
interval. Two-tailed T tests testing for significant differences in PRS scores by subtype were conducted for each cohort 
using a Bonferroni-corrected P threshold of < 0.017.  
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Supplementary Figure 7. Partitioned heritability analysis. The sample size is 16,992 cases and 55,525 controls. The 
coefficient P value (lefthand) tests for enrichment of heritability within each functional element, controlling for all other 
functional elements to address overlap. The enrichment P value (righthand) indicates whether this absolute enrichment is 
statistically significant. In each analysis, the Bonferroni-corrected threshold (vertical line) is -log10(P) > 3.0. The 
enrichment (middle) scales the heritability captured by each functional element according to the number of variants in the 
element (vertical line = 1, that is no enrichment). The error bar is the standard error. 
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Supplementary Figure 8. Cell type group specific partitioned heritability analysis. The sample size is 16,992 cases and 
55,525 controls. The coefficient P value (lefthand) tests for enrichment of heritability within each cell group, controlling for 
all other cell groups to address overlap. The enrichment P value (righthand) indicates whether this absolute enrichment is 
statistically significant. In each analysis, the Bonferroni-corrected threshold (vertical line) is -log10(P) > 2.3 (i.e., 0.05/10 
tests). The enrichment (middle) scales the heritability captured by each cell group according to the number of variants in 
the group (vertical line = 1, that is no enrichment). The error bar is the standard error. 
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Supplementary Figure 9. P value of association between tissue specificity in GTEx and gene-level genetic association 
with anorexia nervosa using MAGMA. The sample size is 16,992 cases and 55,525 controls. The Bonferroni-corrected 
threshold (black vertical line) is -log10(P) > 3.6 and is based on tests across 53 tissues, 24 broad categories of cell types, 
and 149 KI level 2 cell types, a total of 226 tests. 
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Supplementary Figure 10. P value of association between tissue specificity in 24 brain cell types (level 1) and gene-level 
genetic association with anorexia nervosa using MAGMA. The sample size is 16,992 cases and 55,525 controls. The 
Bonferroni-corrected threshold (black vertical line) is -log10(P) > 3.6 and is based on tests across 53 tissues, 24 broad 
categories of cell types, and 149 KI level 2 cell types, a total of 226 tests. 
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Supplementary Figure 11. P value of association between tissue specificity in 149 brain cell types (level 2) and gene-level 
genetic association with anorexia nervosa using MAGMA. The sample size is 16,992 cases and 55,525 controls. The 
Bonferroni-corrected threshold (black vertical line) is -log10(P) > 3.6 and is based on tests across 53 tissues, 24 broad 
categories of cell types, and 149 KI level 2 cell types, a total of 226 tests. 
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Supplementary Figure 12. P value of enrichment of heritability of anorexia nervosa in each tissue in GTEx using LD score 
regression applied to specifically expressed genes (LDSC-SEG). The sample size is 16,992 cases and 55,525 controls. 
The Bonferroni-corrected threshold (black vertical line) is -log10(P) > 3.6 and is based on tests across 53 tissues, 24 broad 
categories of cell types, and 149 KI level 2 cell types, a total of 226 tests. 
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Supplementary Figure 13. P value of enrichment of heritability of anorexia nervosa in brain tissues in GTEx using LD 
score regression applied to specifically expressed genes (LDSC-SEG). The sample size is 16,992 cases and 55,525 
controls. The Bonferroni-corrected threshold (black vertical line) is -log10(P) > 3.6 and is based on tests across 53 tissues, 
24 broad categories of cell types, and 149 KI level 2 cell types, a total of 226 tests. 
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Supplementary Figure 14. P value of enrichment of heritability of anorexia nervosa in cell types in Cahoy database using 
LD score regression applied to specifically expressed genes (LDSC-SEG). The sample size is 16,992 cases and 55,525 
controls. The Bonferroni-corrected threshold (black vertical line) is -log10(P) > 3.6 and is based on tests across 53 tissues, 
24 broad categories of cell types, and 149 KI level 2 cell types, a total of 226 tests. 
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Supplementary Figure 15. P value of enrichment of heritability of anorexia nervosa in 24 brain cell types from the single-
cell RNA-sequencing database (broad categories) using LD score regression applied to specifically expressed genes 
(LDSC-SEG). The sample size is 16,992 cases and 55,525 controls. The Bonferroni-corrected threshold (black vertical 
line) is -log10(P) > 3.6 and is based on tests across 53 tissues, 24 broad categories of cell types, and 149 KI level 2 cell 
types, a total of 226 tests. 
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Additional Methods 
 
Samples and study design 
 
Psychiatric Genomics Consortium (PGC) abbreviations for the 33 datasets meta-analyzed in this 
study are shown in Supplementary Table 1. Supplementary Table 1 shows cohort case and 
control numbers, SNP numbers, and lambda at ascertainment [pre-quality control (QC)] and 
post-QC, Supplementary Table 2 describes ascertainment including how cases were evaluated 
in the primary studies, and case and control sources and inclusion and exclusion criteria. 
Supplementary Table 3 gives the genotyping platforms used. Details of the contributing studies 
and cohorts are provided below. The study is a secondary analysis of data collected from the 
studies described and did not involve direct recruitment and contact with participants or 
collection of identifiers linked to participants. The IRB of the University of North Carolina at 
Chapel Hill gave approval for this project (reference number 15-3307). 
 
Eating Disorders Working Group of the Psychiatric Genomics Consortium (PGC-ED) 
Freeze 1 
Full details of these data are given in the Freeze 1 paper of the PGC-ED 
(http://www.med.unc.edu/pgc) authored by Duncan et al.1 	
To summarize, Duncan et al. datasets included the Children’s Hospital of Philadelphia/Price 
Foundation Collaborative Group (CHOP/PFCG) case-control data from the anorexia nervosa 
GWAS of Wang et al.6, case-only data from the Genetic Consortium for Anorexia 
Nervosa/Wellcome Trust Case Control Consortium-3 (GCAN/WTCCC-3; 
https://www.wtccc.org.uk) included in Boraska et al.2, and since many of the controls used in 
Boraska et al. were not permitted to be re-used, control cohorts were sourced as described in 
Duncan et al.1. Control cohorts from a similar geographic location and genotyped on an Illumina 
platform were preferentially sought. Briefly, eethical approval for each site in GCAN/WTCCC3 
was obtained from the local ethics committee. All participants provided written informed consent 
in accordance with the Declaration of Helsinki1,2. Ethical approval for each site in the PFCG was 
obtained separately from their own institution’s human subjects committee. Informed consent 
was obtained from all study participants3-5. Controls for the PFCG cases were obtained from 
CHOP. The Research Ethics Board of CHOP approved the study, and written informed consent 
was obtained from all subjects or their parents6.	All cases and controls in PGC-ED Freeze 1 were 
also included in the current analysis1. As per Freeze 1, the Italy-North cases from Boraska et al. 
were not included due to a lack of ancestrally-matched controls accessible for our study. Pre-QC 
datasets with < 100 cases were identified (Germany, Greece, Italy-South, Norway) and merged 
with other data to form larger datasets. The combinations were an excellent ancestral match 
according to principal components analysis (PCA). Italy-South and Greece were merged to form 
the cohort itgr. Czech and Poland data were merged and formed the cohort poco, and Norway, 
Germany, and Sweden data were merged and formed the cohort gns2 (see the section below 
called “Genetic Consortium for Anorexia Nervosa/Wellcome Trust Case Control Consortium-3” 
for information about Poland and Sweden data). These samples are included in chop, fin1, fre1, 
itgr, gns2, net1, poco, spa1, ukd1, and usa1 (see the section below for other data in poco and 
gns2). 
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Genetic Consortium for Anorexia Nervosa/Wellcome Trust Case Control Consortium-3 
(GCAN/WTCCC-3) 
Additional GCAN/WTCCC-3 cohorts that were not part of Duncan et al. due to a lack of 
controls (Poland) or small N < 100 of cases (Sweden) were included in our analysis as we were 
able to identify ancestrally matched cases and/or controls. We sourced Poland controls from the 
BoMa/MooDS-PGC study (Bonn/Mannheim Bipolar study; Systematic Investigation of the 
Molecular Causes of Major Mood Disorders and Schizophrenia study)7,8. These controls were 
also used in the PGC bipolar disorder GWAS9. These controls were produced by the 
International Agency for Research on Cancer (IARC; https://www.iarc.fr) and the Centre 
National de Génotypage (CNG; https://www.cng.fr) GWAS Initiative for a study of upper 
aerodigestive tract cancers10 and genotyped on the Illumina HH317k. They were drawn from a 
hospital-based case-control sample recruited by the Nofer Institute of Occupational Medicine in 
Lodz and a population-based case-control sample recruited by the Cancer-Center and Institute of 
Oncology in Warsaw. Controls were not screened for neuropsychiatric phenotypes. These 
combinations above proved an excellent ancestral match according to PCA. These samples are 
included in poco and gns2. 
 
Anorexia Nervosa Genetics Initiative (ANGI) 
ANGI (https://www.med.unc.edu/psych/eatingdisorders/our-research/angi) is a multi-country 
effort to identify the genetic causes of anorexia nervosa and involves international research 
teams in the US, Sweden, Denmark, and Australia with assistance from New Zealand. Details on 
recruitment strategies, case definitions, and methods for ANGI have been reported previously 
and are outlined briefly below11,12. All ANGI controls were screened for eating disorder 
phenotypes and some for additional psychiatric phenotypes. 
 
Australia and New Zealand (ANGI-ANZ).  
Cases from ANGI-ANZ were recruited the following way. Individuals who resided in Australia 
(age ≥ 13 years) or New Zealand (age ≥ 14 years) self-identified or were referred to the study. 
Those interested in study participation completed the consent process and online diagnostic 
questionnaire (ED100K-V1). Cases met anorexia nervosa criteria based on DSM-IV-TR. Once 
the questionnaire was completed, the participant provided a blood sample. In New Zealand, 
witnessed informed consent was obtained prior to sample collection. Genotyping was conducted 
at the Broad Institute on the Illumina Global Screening Array. Controls were obtained from the 
QSkin Sun and Health Study (https://qskin.qimrberghofer.edu.au)13. Briefly, ~40,000 men and 
women aged 40-69 years were randomly sampled from Queensland, Australia. Those who 
indicated no eating disorders history from a checklist were included as controls. QSkin was 
established to study the etiology of cutaneous melanoma and other cancers of the skin; the cohort 
is followed up passively through linkage with health registers. QSkin participants provided 
Oragene saliva samples, and DNA was genotyped at Erasmus University Rotterdam in the 
Netherlands on the Illumina Global Screening Array. Ethical approval for the Australian 
component of the study was provided by the QIMR Berghofer Human Research Ethics 
Committee (QIMR-HREC approval P1339). Those interested in study participation completed 
the informed consent process via online submission prior to taking an online diagnostic 
questionnaire (ED100K-V1). Participants younger than 18 years then completed a paper 
questionnaire which required parent/guardian co-signature. Ethical approval for the New Zealand 
component was provided by the Health and Disability Ethics Committee of the New Zealand 
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Ministry of Health. In New Zealand, witnessed informed consent was obtained prior to sample 
collection. Participants under 18 years required parent/guardian co-signature. Ethical approval 
for the QSkin study was provided by the Human Research Ethics Committee of the QIMR 
Berghofer Medical Research Institute (QIMR-HREC approval P1309). QSkin participants were 
given the option to provide written informed consent or to consent online in order to take part in 
the QSkin study. The samples described formed cohort aunz. 
 
Denmark (ANGI-DK). National register and biobank. Cases and controls were identified 
primarily using the national register and biobank system. Genotypes came from Guthrie cards 
held by the Danish Neonatal Screening Biobank at Statens Serum Institute. Samples from this 
biobank are linked to the Danish register system via the unique Danish personal identification 
number. The individuals were born between 1981 and 2005 and had to be alive and a resident of 
Denmark on their first birthday and have a known mother. Cases had International Classification 
of Diseases (ICD-10) anorexia nervosa (F50.0)14 diagnoses assigned by psychiatrists at inpatient 
and outpatient psychiatric services, and were identified using the Danish Psychiatric Central 
Research Register15. Controls were randomly selected from the same nationwide birth cohort. 
Cases and controls were specifically ascertained and genotyped as a part of ANGI, and 
additional control genotypes came from the Lundbeck Foundation Initiative for Integrative 
Psychiatric Research (iPSYCH; http://ipsych.au.dk)16. DNA from the dried blood spots was 
extracted, whole-genome amplified in triplicates, and genotyped in 23 batches based on birth 
year. The first wave (batch) contains the youngest participants (born in 2004) and wave 23 
consists of the oldest participants (born in 1981). Wave 24, a supplementary batch, comprised all 
participants with an ICD-10 atypical anorexia nervosa lifetime diagnosis (F50.1, most commonly 
diagnosed when all anorexia nervosa criteria except amenorrhea were met) up to and including 
2013 and F50.0 cases diagnosed during 2013. Comparisons showed that F50.0 and F50.1 
samples matched on register information tested, i.e., age of diagnosis, frequency of lifetime 
psychiatric diagnoses and intellectual disability, urbanicity, and maternal and paternal age at 
childbirth. Genotyping was performed on the Illumina PsychChip array at the Broad Institute of 
Harvard and MIT. GenCall17 and Birdseed18 were used to call variants with MAF > 0.01. Call 
sets were merged after pre-QC on individual call sets. Data processing and GWAS analyses were 
performed on secure servers at the GenomeDK high-performance computing cluster 
(http://genome.au.dk).  
 
DNA preparation, genotyping, genotype calling, QC methods, and imputation were performed 
on the broader iPSYCH cohort waves, which also included psychiatric cases with non-anorexia 
nervosa diagnoses (schizophrenia, depression, bipolar disorder, autism spectrum disorder, and 
attention-deficit/hyperactivity disorder). The full iPSYCH cohort described contains ~86,000 
individuals, including about 57,000 cases with at least one of the noted psychiatric disorders and 
around 30,000 controls. Each wave that was processed had ~3,500 participants.  
 
Case-control data were filtered for the primary GWAS analysis such that cases required an 
anorexia nervosa or atypical anorexia nervosa lifetime diagnosis and controls required no 
lifetime anorexia nervosa or iPSYCH psychiatric diagnoses listed above. To address batch 
effects, a GWAS was conducted on waves separately, except waves 1 to 6 which were combined 
in a block due to smaller case sample sizes. Ancestry principal components (PCs) and PCs that 
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captured batch effects and other possible sources of variation were included as covariates 
(Supplementary Table 18). ANGI-DK samples formed cohorts w1 to w24. 
 
Individuals in ANGI-DK did not provide written informed consent. The register data collection 
is pseudo-anonymized (http://ipsych.au.dk/about-ipsych/data-processing-and-data-security-
atipsych) and the re-identification key for linking the Danish civil registration number is stored 
separately from phenotype and genotype data. An exemption from consent is legally possible in 
Denmark if approved by The Danish Scientific Ethics Committee (Videnskabsetisk Komité). 
This exemption was given for all samples and was provided in 2012 to the iPSYCH study, with 
the most recent approval granted in 2018. 
 
Denmark clinic samples. A Danish clinical cohort was obtained. Cases were defined as patients 
with at least one recorded hospital admission during which an ICD-1014 diagnosis of F50.0 or 
F50.1 was given. Clinical cases consisted of women born 1947-1980 (age range: 35 to 68 years). 
Samples were genotyped at the Broad Institute on the Illumina Global Screening Array. Ethical 
approval with the protocol no. H-KF-01-024/01 was obtained from the competent Danish 
authority, De Videnskabsetiske Komiteer for Region Hovedstaden (The Capital Region of 
Denmark’s Committees on Health Research Ethics). All participants provided written informed 
consent prior to being included into the study. The samples described are included in cohort 
sedk. 
 
Sweden (ANGI-SE). The primary recruitment strategy involved Riksät-National Quality 
Register for Eating Disorders Treatment19, which includes eating disorder-specific information 
from individuals seeking eating disorder treatment in Sweden since 1999. Potential cases 
identified through Riksät were sent a letter asking them to complete a follow-up questionnaire, 
which included the ED100K-V1 questionnaire. In the second recruitment strategy, study nurses 
at the Stockholm Centre for Eating Disorders (http://stockholmatstorningar.se) (SCÄ) recruited 
cases for ANGI. When patients with anorexia nervosa came into this center, a research nurse 
discussed the study with them and reviewed the consent. When participants consented, a blood 
sample was taken, and the participant was directed to complete the online diagnostic 
questionnaire. The third strategy was community outreach, specifically using traditional media 
(i.e., TV, radio, and newspapers) and social media including the Swedish ANGI website 
(http://www.angi.se), directly linking to the questionnaire. The final recruitment strategy for 
cases and controls involved LifeGene (https://www.lifegene.se)20, an ongoing study initiated in 
2010 to evaluate how genes, environment, and lifestyle affect health. Individuals enrolled in 
LifeGene completed an eating disorder assessment similar to the online diagnostic questionnaire 
and provided a blood sample. An anorexia nervosa algorithm for LifeGene was harmonized with 
the ED100K-V1 questionnaire for case and control identification. All cases met anorexia nervosa 
criteria based on DSM-IV-TR21, and controls screened negative for a history of eating disorders. 
Genotyping was performed at the Broad Institute on the Illumina Global Screening Array. The 
Swedish component of ANGI (Riksät, SCÄ, and Community) was approved by the Regional 
Ethical Review Board in Stockholm (dnr: 2013/112-31/2). Individuals who wished to participate 
were mailed consent forms along with the vials for blood samples. Signed consent forms were 
returned with the samples. The Regional Ethical Review Board of Stockholm provided initial 
ethical approval of LifeGene. All participants provided consent online20. The Swedish 
component of ANGI obtained approval, as stated above, for use of LifeGene samples and data as 
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part of ANGI-SE. These samples described are included in cohort sedk (see the section above 
called “Denmark Clinic Samples” for other samples included in sedk. 
 
United States (ANGI-US). Individuals who resided in the US (ages ≥ 12 years) self-identified 
or were referred to the study. Individuals completed a brief online screener to determine 
eligibility as a case or control for ANGI. Those deemed eligible completed the consent process 
and online diagnostic questionnaire (ED100K-V1). All cases met anorexia nervosa criteria based 
on DSM-IV-TR, and controls screened negative for a history of eating disorders. Once the 
questionnaire was completed, the participant provided a blood sample. Approximately 1,000 
controls were recruited from the community. Additional control samples were obtained from The 
Price Foundation Anorexia Nervosa Trios Study5,22. These additional controls reported no history 
of eating disorders, had no first degree relative with an eating disorder, and screened negative for 
other Axis I psychopathology. Genotyping was performed at the Broad Institute on the Illumina 
Global Screening Array. Ethical approval for the US component of ANGI was granted by the 
University of North Carolina at Chapel Hill’s Institutional Review Board (IRB# 13-0081). 
Individuals who were interested in study participation (and deemed eligible by the brief screen in 
the US) contacted the study team and completed the consent process. Although some provided 
written consent, most participants provided consent over the phone after a complete review of 
the consent forms. These samples formed cohort usa2. 
 
UK Biobank 
The UK Biobank (http://www.ukbiobank.ac.uk/) is a large prospective study of ~500,000 
residents of the United Kingdom aged from 40 to 69 years old23. UK Biobank aims to provide 
insights into the causes, prevention, and treatment of various illnesses. Recruitment occurred 
between 2006-2010. The present study uses data from the July 2017 release including the second 
wave of genetic data. Cases were identified by primary and secondary ICD-1014 diagnosis from 
linked health care records and self-report diagnosis of anorexia nervosa by a clinical professional 
in the UK Biobank mental health questionnaire. Controls were screened for any psychiatric 
disorder (Chapter V: Mental and behavioral disorders). UK Biobank participants provided 
electronic signed consent at their baseline assessment visit. UK Biobank was approved by the 
NHS Health Research Authority North West-Haydock Research Ethics Committee (reference 
16/NW/0274). The current study was completed as part of approved UK Biobank application 
27456. The samples described formed cohort ukbb. 
 
Merging of case and control data 
 
When sourcing control data, we prioritized controls that were ancestrally matched and genotyped 
on a similar platform to cases. There are two instances whereby cases were matched with 
controls from another country [i.e., aunz New Zealand cases (n = 430) were merged with 
Australian cases (n = 2,261) and controls (n = 17,158), and sedk Denmark cases (n = 129) were 
merged with Sweden cases (n = 4,118) and controls (n = 4,035)]. Country is unlikely to be 
confounded with case-control status in these cohorts. Ancestral matching was undertaken by 
visual inspection of a principal components analysis PC1 v PC2 plot for the merged data, and the 
matches were excellent with cases and controls randomly interspersed. Further, the first five 
ancestry PCs and any PCs that significantly differed (P < 0.05) between case and control cohort 
were included as covariates in GWAS to capture nuanced ancestry or batch effect differences.  
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Statistical power 
 
Identified susceptibility variants in psychiatric genetics typically have an OR of ~1.124. Our 
study was acceptably powered to detect susceptibility variants in this range (80% power to detect 
an OR of 1.09-1.19 with an additive model, 0.9% lifetime risk25, α = 5 × 10-8, MAF 0.05–0.5). 
Prior experience in other PGC disorders gives us reason to believe that when sample sizes reach 
an inflection point for power to detect multiple GWAS hits, the number of significant loci begins 
to increase linearly as samples were added after this inflection point. It is not surprising to see 
several borderline significant hits when first exceeding the inflection point, as has been observed 
in schizophrenia26-28. As more cases are added, it is probable that we will get more lead hits 
above this borderline range. 
 
Quality control and covariates 
 
For the GWAS analysis, the default QC parameters in Ricopili were used and are described as 
follows. Ricopili QC begins with a pre-filter SNP call rate of > 0.95, which is useful for cases 
and controls genotyped on different platforms. Next, QC involves sample filters, then SNP 
filters. Default sample filters are a call rate (cases/controls) ≥ 0.98, heterozygosity inbreeding 
coefficient ≤ 0.2 (cases/controls), and sex violations. Default SNP filters are a call rate ≥ 0.98, 
case-control missingness difference ≤ 0.02, no valid association P value (invariant), and 
violations of Hardy-Weinberg equilibrium (in controls P > 10-6, in cases P > 10-10). Some 
cohorts required the application of more stringent thresholds to reduce bias (Supplementary 
Table 18). Ancestry outliers were removed based on plotting the first two principal components 
(PCs) in a principal components analysis (PCA) containing each cohort and five reference 
cohorts (1000 Genomes Phase 3 EUR, AFR, EAS, SAS, AMR)29 to retain European samples. 
Samples showing familial structure and/or cryptic relatedness, or duplicates were removed (𝜋" > 
0.2) during PCA. For the Danish waves, we conducted additional relatedness testing across all 
the waves combined, and then removed one individual from each related pair (𝜋" > 0.2). PCs 
significantly associated with the phenotype were identified for inclusion as covariates. For the 
aunz cohort, QC and PCA was done externally. For QC, see Supplementary Table 18. PCA (20 
principal components) were computed using smartpca (EigenSoft 6.0.1) on the cleaned data from 
all individuals used in the current paper in conjunction with the genotypes of ~50,000 additional 
individuals available at QIMR Berghofer, and the population reference data from the Genome-
EUTWIN populations (https://ega-archive.org/datasets/EGAD00000000043) and HapMap Phase 
3 populations30. Analyses were run using a filtered set of genotypes available across all 
genotyping projects (N SNPs ~40,000). Individuals beyond six standard deviations (SDs) of the 
European PC1 and PC2 centroid were excluded from analysis. The data were then put through 
Ricopili PCA module; the first five ancestry components and PCs significantly associated with 
the phenotype were always included as covariates (Supplementary Table 18). To the extent that 
national laws and regulations permitted, we examined sample overlap across cohorts by 
performing LD score bivariate regressions and estimating genetic covariance intercepts to assess 
sample overlap31,32 (Supplementary Table 19). 
 
Some of the cohorts required additional QC beyond the default process and parameters used in 
PGCs GWAS pipeline, Ricopili. Supplementary Table 18 shows the additional QC steps 
applied, if any, and the PCs used as covariates, by cohort. The first five PCs were automatically 
17 
 
 
included to adjust for ancestry effects. Tests were done on post-QC data to investigate whether 
any of the PCs differ significantly between cases and controls, and if so, PCs nominally 
associated with the phenotype (P < 0.05) were also included in the GWAS as covariates. 
 
Anorexia nervosa subtype phenotypes 
 
We defined subtypes based on the presence or absence of binge eating. The rationale for this 
choice was that the current DSM-533 subtyping (i.e., restricting versus binge/purge) is a clinical, 
rather than a biological distinction. “Purging” behavior is a heterogeneous category and includes 
several behaviors either alone or in combination (e.g., self-induced vomiting, laxative abuse, 
diuretic abuse, other inappropriate compensatory behaviors), and our sample size is insufficiently 
powered—and phenotyping in several samples inadequately detailed—to identify individuals 
with various purging behavior constellations. In contrast, binge eating is more uniformly defined, 
represents a clear departure from restrictive eating behavior, and lies on the appetite continuum. 
Although the twin-based genetic correlation between binge eating and self-induced vomiting is 
high (rg = 0.74)34, less is known about other purging methods. Larger samples sizes will enable 
additional group distinctions and allow us to comment on the biological appropriateness of the 
current DSM-5 subtypes. 
  
We defined anorexia nervosa with and without binge eating using available phenotypic data. We 
were able to use chop, aunz, and usa2 datasets for this analysis. For aunz (ANGI-ANZ) and usa2 
(ANGI-US), anorexia nervosa with binge eating was defined as reporting ever 1) "having eating 
binges when you ate what most people would regard as an unusually large amount of food in a 
short period of time" and 2) "having a sense of loss of control during those eating binges". The 
absence of binge eating was determined by a “no” answer to either item. For chop 
(CHOP/PFCG), the presence of binge eating was defined as reporting a history of binge eating 
by structured or semi-structured interview. The no binge eating group had to report no lifetime 
history of bulimia nervosa and no history of binge eating. Purging was not used in these 
definitions and binge eating did not need to occur within episodes of anorexia nervosa. The 
percentage of available subtype data within these cohorts was 95% overall. Future analyses with 
larger samples sizes will increase confidence in results from this analysis. 
 
GWAS of related traits in UK Biobank 
 
Seven UK Biobank GWAS were performed to facilitate genetic correlation investigations. The 
phenotypes were BMI (Hübel, Gaspar, Coleman, Hanscombe, Purves…Breen, unpublished 
report), body fat percentage35, fat mass (Hübel, Gaspar, Coleman, Hanscombe, Purves…Breen, 
unpublished report), fat-free mass35, physical activity35, anxiety36, and neuroticism35.  
 
Genotyping, imputation and QC 
Briefly, blood samples were genotyped on two arrays, which share nearly all of their content: the 
UK BiLEVE array (N = 49,949) or the UK Biobank Axiom array (N = 438,414). Genotyping 
was conducted by Affymetrix across 33 different batches of approximately 4,700 samples each. 
UK Biobank provides extensive information on sample processing on its website 
(biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=155583). UK Biobank performed stringent QC on the 
genotyping data at the Wellcome Trust Centre for Human Genetics (WTCHG). For further 
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details, see: biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=155580. Prior to imputation, all variant 
sites with a call rate below 90% were filtered out. Imputation was carried out by UK Biobank 
using a merged UK10K-1000 Genomes Phase 3 reference panel and the Haplotype Reference 
Consortium (HRC) panel37 (for further information, please see 38). UK Biobank preferentially 
retained SNPs imputed to HRC for SNPs present in both imputation panels. Imputation was 
conducted using the IMPUTE4 program38. 
 
We excluded non-European participants identified by k-means clustering (k = 4) on the first two 
PCs derived from the genotype data, and related individuals (KING relatedness metric > 0.088, 
equivalent to an identical-by-descent coefficient of 0.25). SNPs were excluded if they had a 
MAF < 1%, if no call was made in > 2% of samples following imputation, if they were imputed 
with low confidence (INFO < 0.8), deviated substantially from Hardy-Weinberg equilibrium 
(HWE test, P < 10-7), if they were not genotyped and were not part of the HRC panel. Additional 
QC and other information about these GWAS is given in Supplementary Table 20. 
 
GWAS of BMI, body fat percentage, fat mass, and fat free mass 
The GWASs on BMI, body fat percentage, fat mass, and fat free mass were a cross-sectional 
analysis of 155,961 healthy European participants from the UK Biobank. To identify genetic 
variation uniquely associated with body composition not confounded by illnesses and their 
downstream effects or metabolism-altering medication, we applied stringent exclusion criteria 
(e.g., psychiatric, gastrointestinal and endocrine illnesses, hormonal and antidiabetic 
medication). Body composition was assessed using Tanita BC-418 MA scale (Tanita 
Corporation, Arlington Height, IL). We included 7,794,483 genotyped and imputed SNPs and 
insertion-deletion variants with a MAF ≥ 1%. We covaried for assessment center, genotyping 
batch, smoking status, alcohol consumption, menopause, age, and socioeconomic status 
(measured by the Townsend Deprivation Index)39. We accounted for underlying population 
stratification by including the first six ancestry PCs, calculated on the European subsample 
GWAS cohorts. We used BGENIE v1.2 (https://jmarchini.org/bgenie) for sex-specific analyses 
and meta-analyzed these sex-specific GWAS using METAL40 
(http://csg.sph.umich.edu/abecasis/metal).  
 
GWAS of physical activity 
We calculated sex-specific GWAS of physical activity with imputed genotype data in 29,496 
male and 36,758 female (N = 66,254) individuals in the UK Biobank, including age (at 
recruitment), genotyping array, and genetic PCs 1–20 as covariates. Physical activity in the UK 
Biobank was measured continuously over a period of seven days with a wrist-worn 
accelerometer. General physical activity quality control of raw data is described in detail 
elsewhere41. They used a wear-time adjusted 7-day average measure of activity, including only 
individuals meeting UK Biobank QC criterion: good wear-time, good calibration, calibration on 
own data, and no problem indicators. Analyses were performed on the intersection of this UK 
Biobank subset with those passing general genotyping QC: in European ancestry subset; used in 
the calculation of ancestry PCs; without excess relatives in the UK Biobank sample; no putative 
sex chromosome aneuploidy; and were not outliers for heterozygosity and genotype missingness. 
General genotyping considerations, raw data QC, and imputation procedure in the UK Biobank 
are described in detail elsewhere38. 20 PCs provided by the UK Biobank were used.  
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GWAS of anxiety 
We conducted sex-specific GWAS of anxiety disorders with imputed genotype data on 25,443 
cases and 58,113 controls36. Cases met criteria for probable lifetime anxiety disorder diagnosis if 
they either self-reported a professional diagnosis of any of the five core anxiety disorders 
(generalized anxiety disorder, panic disorder, specific phobia, agoraphobia, or social anxiety 
disorder) or met criteria for probable lifetime generalized anxiety disorder according to the 
Composite International Diagnostic Interview question set42,43. Cases did not report a diagnosis 
of schizophrenia, psychosis, attention-deficit/hyperactivity disorder (ADHD), autism, any eating 
disorder, or bipolar disorder. Controls were screened for any evidence of psychiatric or substance 
use disorders. Participants were limited to individuals of European ancestry, who were not 
excessively related, had no putative sex chromosome aneuploidy, and were not outliers for 
heterozygosity and genotype missingness. Stratified linear regressions were performed on ~7 
million SNPs of high imputation quality (INFO > 0.9) with a minimum MAF ≥ 0.01 in BGENIE 
v1.2 controlling for six ancestry PCs calculated on the European subsample of UK Biobank, 
assessment center, genotyping batch, and age. 
 
GWAS of neuroticism 
We performed sex-specific GWAS on neuroticism using the genotype data supplied by UK 
Biobank in males (N = 142,875) and in females (N =144,660; total N = 287,535), following QC 
as described above and using PCs calculated on the European subsample of UK Biobank. The 
neuroticism phenotype was calculated as the sum score of neuroticism questions at the baseline 
assessment44, corrected for age and sex-specific means and SDs from the UK population45. In a 
second analysis, individuals were excluded if they reported any psychiatric illness resulting in 
83,413 males and 73,946 females (total N = 157,355). Sex-stratified linear regressions were 
performed in PLINK using eight ancestry PCs and genotyping batch (as a factor) as covariates 
and later meta-analyzed using METAL40. 
 
Gene expression 
 
We first investigated whether anorexia nervosa heritability was enriched in tissue/cell type 
specifically expressed genes using publicly available gene expression data: GTEx46 (RNA-seq of 
macroscopic samples from multiple human tissues) and Cahoy47 (mouse neural cell-types 
transcriptome database). Stratified LDSC estimated common variant heritability enrichment in 
the top 10% of specifically expressed genes in each tissue or cell type, taking into account 
confounders such as gene size, LD, and functionally enriched genomic regions (e.g., conserved 
regions across mammals48. We followed a published method LDSC-SEG (LDSC applied to 
specifically expressed genes)49. From the datasets, the method has derived a genome annotation 
corresponding to each tissue or cell type of interest, which contains the top 10% specifically 
expressed genes of the tissue or cell type together with 100 Kb windows on each side of the 
transcribed region of each genes. We obtained the derived genome annotations from the LDSC-
SEG GitHub repository (https://github.com/bulik/ldsc).  
 
Second, we created a new annotation by performing differential expression analyses among 
9,970 single cells, previously clustered into 24 different cell types50, from five different mouse 
brain regions. Briefly, we used the scran R package51 using the 50% of the genes with mean 
expression higher than the median to compute normalization factor for each single cell. The 
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normalization factors were computed after clustering cells using the scran package quickCluster 
function to account for cell type heterogeneity. We then performed 24 differential expression 
analysis using R package BPSC52 testing each cell type against the 23 other cell types using the 
computed normalization factors as a covariate. We then selected the top 10% most upregulated 
genes for each cell type and used the coordinates of these genes extended by 100 Kb on each side 
as an extra annotation in LDSC. 
 
We used the “munge_sumstats.py” script built in the LDSC software31,32 to reformat the ANGI 
GWAS results. We then applied stratified LDSC regression to estimate heritability enrichment of 
the annotations49 (tissue or cell type) conditional on 53 other annotations from the “baseline 
model” (e.g., conserved regions48). We used regression weights computed from phase 3 of the 
1000 Genome Project29 with HLA regions removed 
(https://data.broadinstitute.org/alkesgroup/LDSCORE/1000G_Phase3_weights_hm3_no_MHC.t
gz). 
 
We primarily report the regression coefficient of each annotation (corresponding to gene 
expression of each tissue or cell type) and an associated P value. A positive regression 
coefficient suggests that the annotation contributes to the heritability of anorexia nervosa while 
accounting for the contributions of other annotations49,53. The P value tests whether the 
regression coefficient was significantly positive (one-tailed), i.e., whether the contribution of the 
annotation is statistically significant. LDSC analyses are reported in Supplementary Figs. 12-
15. 
 
We also used MAGMA54 (v1.06) (https://ctg.cncr.nl/software/magma), as done previously50, to 
identify tissues/cell types underlying anorexia nervosa. GTEx data (V6p, median expression 
across individual per tissue) was downloaded from the GTEx website 
(https://gtexportal.org/home). Genes not expressed in any tissues (median = 0 for all tissues) 
were excluded. Gene expression from the different brain cell types was obtained as previously 
described. Briefly, we performed single cell RNA-seq from 9,970 single cells from five brain 
regions (neocortex, hippocampus, hypothalamus, striatum, midbrain, plus samples enriched for 
oligodendrocytes, dopaminergic neurons, and cortical parvalbuminergic interneurons), which 
allowed us to identify 24 cell types at level 1 (broad clustering) (pyramidal neurons, 
oligodendrocytes, etc…) and 149 cell types at level 2 (fine grained clustering) (pyramidal 
neurons from layer 6, layer 4, etc…). 
 
For each gene expression dataset, we computed an index of specificity for each gene in each 
tissue/cell type by dividing the expression of a gene in a given tissue/cell type by the total 
expression of the gene in all tissues/cell types (range of specificity: 0-1). For each tissue/cell 
type, we then binned the specificity measure into 41 bins (0 representing a gene not expressed in 
the tissue/cell type, 1 gene in the bottom 2.5% quantile of specificity, …, 40 genes that are in the 
97.5% to 100% most specific genes in the tissue/cell type). We then used MAGMA to test for a 
positive correlation between binned tissue specificity and gene-level genetic association with 
anorexia nervosa for each tissue/cell type. The gene-level genetic association was computed with 
MAGMA (v1.06) using a window surrounding the gene by 35 kb upstream to 10 kb downstream 
of the gene. The gene-level association is computed by summing the association P value of SNPs 
located in the gene windows taking into account the LD structure of the region. MAGMA takes 
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into account confounders such as gene length, LD, and gene-gene correlation. MAGMA analyses 
are reported in Supplementary Figs 9-11. 
 
Predicted tissue-specific gene expression 
 
We predicted differential gene expression using S-PrediXcan v1.055 and genomic and 
transcriptomic reference data from the brain regions assayed in the GTEx project v746 and 
Depression Genes and Networks (DGN) whole-blood cohort56. A total 258,158 gene-tissue pairs 
were tested (Supplementary Table 13). Significant genes were compared to genes in the gene-
wise analysis performed with MAGMA.  
 
A general note on multiple testing correction 
 
Carrying out multiple testing runs the risk of inflating Type I error and increases the probability 
of false positive results. To manage this risk, we took the general approach of setting a 
conservative a priori P Bonferroni correction threshold. We did this generally on a within-
analysis basis, since different analyses tested different underlying hypotheses, rather than paper-
wide. Readers can identify the Bonferroni threshold used for a given analysis in Table and Figure 
notes. 
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Additional Results 
 
Primary GWAS meta-analysis 
 
Pre- and post-QC lambda, number of single-nucleotide polymorphisms (SNPs), and Ns in each 
of the final 33 datasets analyzed within the primary GWAS can be found in Supplementary 
Table 1. The meta-analysis LD intercept was 1.02 (s.e. = 0.01). The meta-analysis quantile-
quantile (Q-Q) plot is shown in Supplementary Fig. 1. The LD score regression intercepts for 
each cohort after QC ranged from 0.98 (s.e. = 0.01) to 1.03 (s.e. = 0.01) (Supplementary Table 
1). The genetic covariance intercepts in LD score bivariate regression analyses were close to 0 
and indicated no evidence of sample overlap among the cohorts (Supplementary Table 19). 
Eight genome-wide significant loci were identified. Follow-up analyses included using genome-
wide complex trait analysis (GCTA-COJO)57 to conduct stepwise regression on markers with P 
values < 10-8. GCTA-COJO identified eight independent signals taking into account the LD 
correlations between SNPs and running a conditional and joint analysis58. All eight identified 
markers were equivalent to the SNPs resulting from distance- and LD-based clumping shown in 
Table 1 (for conditional analyses please see Supplementary Table 5).  
 
Genomic inflation and residual confounding 
Here we provide detailed information to illustrate that confounding due to population 
stratification or other reasons was minimal in our primary GWAS. Two relevant parameters were 
estimated using linkage-disequilibrium (LD) score regression29. Firstly, we estimated an LD 
intercept of 1.02 (s.e. = 0.01) for the meta-analysis and between 0.98-1.03 for individual datasets 
(Supplementary Table 1). The LD score intercept is significantly greater than one, but is in line 
with the expected small levels of inflation caused by sample size and heritability described in 
Loh et al.59. A second measure, the attenuation ratio [(LDSC intercept – 1) / (mean χ2 – 1)] for 
the meta-analysis was 0.07 (s.e. = 0.04) (Supplementary Fig. 1), also suggesting a lack of 
confounding. Together these suggest that deviation from the null was due to polygenic signal and 
not population structure or bias.  
 
The overall inflation of summary statistics genomewide or λGC for individual datasets post-QC 
ranged between 1.00-1.06 (Supplementary Table 1) and for the meta-analysis was 1.22 
(Supplementary Fig. 1). Inflation of tests statistics is known to be due to a combination of 
polygenicity, uncorrected population stratification, and confounding. The larger λGC value 
observed for our GWAS meta-analysis is indeed expected at this sample size, trait polygenicity, 
and heritability59. The LD score regression method for GWAS of highly polygenic phenotypes 
such as anorexia nervosa and large sample sizes separates the polygenetic component (the slope) 
from population stratification and other systematic biases (estimated by the intercept and 
attenuation ratio) 29. 
 
Correcting for λGC in large GWAS samples of polygenic phenotypes can cause loss of signal and 
power, as evidenced by the LD intercept of the GWAS summary statistics from the Genetic 
Investigation of Anthropometric Traits (GIANT) Consortium 2015 body mass index (BMI) 
paper (0.65)60,61. Correction for λGC at the individual study level has also been shown to bias 
heritability estimates downward29.  
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Previous hit 
The chr12 locus identified in Duncan et al.1 did not reach genome-wide significance. The OR for 
the index variant at this locus (rs4622308) was in the same direction in the present meta-analysis 
compared with Duncan et al. (present: A1 = C, A2 = T, OR = 1.06, s.e. = 0.01, P = 7.02 × 10-5; 
Duncan et al.: A1 = C, A2 = T, OR = 1.20, s.e. = 0.03, P = 4.25 × 10-9 ) and in 22 of the 33 
cohorts (z = 2.00, P = 0.05, 2-tailed). To further assess this locus, a random-effects meta-analysis 
was conducted. Similar to the fixed-effect meta-analysis, the random-effects meta-analysis 
indicated that the effect of this locus was not genome-wide significant (OR = 1.06, s.e. = 0.05, P 
= 0.02) and showed evidence of heterogeneity, I2 = 53.7 (Supplementary Fig. 4). There are 
many possible reasons why the result was not replicated, including winner’s curse62, moderator 
variables given the heterogeneity observed (such as environmental risks), between-study 
heterogeneity in ascertainment, and differences in LD structure across cohorts in addition to true 
non-replication.  
 
Chromosome X 
The separate analysis of chrX included n = 14,915 cases and n = 27,854 controls. There were no 
genome-wide (P < 5 × 10-8) or suggestive (P < 1 × 10-5) significant loci.  
 
Female-only secondary GWAS 
 
A supplementary analysis conducted on female cases and controls only—to determine the 
similarity of results to the main GWAS analysis which included females and males—had 14,896 
cases and 27,865 controls. The female-only GWAS revealed one genome-wide significant locus 
(P < 5 × 10-8) on chr3 (rs9812977; 48.2-49 Mb; P = 1.31 × 10-9; OR = 1.08; 95% CI: 1.03-1.14), 
which was the top locus in the main GWAS analysis. 
 
eQTL and Hi-C interactions 
 
For locus 1 (multigenic, chr3:47.5-51.3 Mb, Supplementary Fig. 5a), our data implicate 100 
brain-expressed genes. Locus 1 is gene-dense with a large number of brain eQTLs and regulatory 
chromatin interactions. Notably, 16 genes with regulatory chromatin interactions mapping to the 
locus lie outside the LD-defined locus. Locus 3 (multigenic, chr2:53.8-54.3 Mb, Supplementary 
Fig. 5c) is less complex that locus 1. Nonetheless, we implicate 12 genes, six within and 6 
outside the LD-defined locus.  
 
For all four single-gene loci, eQTL and/or chromatin interaction connections implicated the gene 
intersecting the locus. For locus 2 (chr11:114.9-115.4 Mb, Supplementary Fig. 5b), both eQTL 
and regulatory chromatin interaction data confirmed the connection to the locus-intersecting 
gene CADM1. Genetic variants near to CADM1 (cell adhesion molecule 1) have been implicated 
by GWAS for body mass and age at menarche. CADM1 protein levels appear to be elevated in 
the hypothalamus of BMI risk variant carriers. Obese mice have been reported to show elevated 
CADM1 expression and CADM1 knockout mice show reduced body weight63. For locus 4 
(chr10:131.2-131.4 Mb, Supplementary Fig. 5d), eQTL data connected to the locus-intersecting 
gene MGMT. MGMT (O-6-methylguanine-DNA methyltransferase) encodes an epigenetic 
regulator important in multiple cancers, including glioblastoma. For locus 5 (chr3:70.6-71.0 Mb, 
Supplementary Fig. 5e), regulatory chromatin interaction data confirmed the connection to the 
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locus-intersecting gene FOXP1 (forkhead box P1), which encodes a transcription factor in the 
forkhead box family. Brain-specific deletion of FOXP1 results in defects in striatal development 
and changes in the hippocampus64. Interestingly, FOXP1 knockout mice exhibit a significant 
reduction in body weight as compared to littermate controls. For locus 5, eQTL data also 
suggested a functional connection to the more distal GPR27, which encodes an orphan G-protein 
coupled receptor, and is highly expressed in the brain65. It has recently been associated with 
insulin secretion66. Finally, for locus 6 (chr1:96.6-97.2 Mb, Supplementary Fig. 5f), both eQTL 
and regulatory chromatin interaction data confirmed the connection to the locus-intersecting 
gene PTBP2. The protein encoded by this gene binds to intronic polypyrimidine clusters in pre-
mRNA molecules and is implicated in controlling the assembly of other splicing-regulatory 
proteins. 
 
One intergenic locus (locus 8, chr5:93.9-95.0 Mb, Supplementary Fig. 5h) had eQTL 
connections to PROS1 and ARL13B. PROS1 encodes an anticoagulation factor that plays a role 
in blood-brain-barrier integrity67. ARL13B encodes a member of the ADP-ribosylation factor-like 
(ARL) small Ras GTPase family. ARL13B protein is expressed in the cilia of all organs; 
mutations are associated with Joubert syndrome 8, which like other ciliopathies has been 
associated with obesity68,69. Mutations are also associated with intellectual disability (University 
of Chicago’s Intellectual Disability Exome Panel). Thomas et al.69 found ARL13B expression 
throughout the developing human brain. Additionally, they identified ARL13B expression in 
primary cilia of hypothalamic neurons of newborn mice. Furthermore, Higginbotham et al.70 
found that mutant ARL13B disrupts the development and migration of interneurons.  
 
For locus 7 (intergenic, chr5:24.9-25.3 Mb, Supplementary Fig. 5g), there were no supporting 
eQTL or regulatory chromatin interactions. 
 
Multi-trait conditional and joint analysis (mt-COJO) 
 
Seven of the eight genome-wide significant loci showed only slight changes in their effect sizes 
(i.e., betas) after conditioning on education years71, type 2 diabetes72, high-density lipoprotein 
(HDL) cholesterol73, BMI (Hübel, Gaspar, Coleman, Hanscombe, Purves…Breen, unpublished 
report; see Additional Methods), schizophrenia28, or neuroticism35. The results suggest that the 
loci are independent of the traits on which they were conditioned and that the traits may not 
share genetic association at these loci. The association of locus 2 on chr11 tagged by rs6589488 
with anorexia nervosa may not be independent of genetic associations with type 2 diabetes as the 
beta was diminished after conditioning. This suggests, at locus 2, that the association with 
anorexia nervosa may not be independent of genetic underpinnings of glycemic alterations seen 
in type 2 diabetes.  
 
Clinical investigations 
 
Anorexia nervosa subtype  
One potential source of genetic heterogeneity lies in differing clinical presentations of anorexia 
nervosa (i.e., with or without the presence of binge eating). This was not supported in 
preliminary analyses. The SNP-based genetic correlation (SNP-rg) between the anorexia nervosa 
subtypes was 0.74 (s.e. = 0.16; P = 1.74 × 10-6). To test for heterogeneity in the genetic variation 
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associated with these two subtypes, we tested whether their SNP-rg was significantly different 
from unity. We used a block jackknife approach using the LD score regression software (LDSC) 
v1.029. The genetic correlation between anorexia nervosa with and without binge eating was not 
significantly different from 1 (P = 0.08). There were no significant differences in the mean 
polygenic risk score (PRS) between subtypes in the three cohorts for which anorexia nervosa 
subtype data were available (Supplementary Fig. 6). We also calculated SNP-rg by anorexia 
nervosa subtype (Supplementary Table 9) and found no significant differences in SNP-rg with 
external traits, although small sample sizes limit interpretation. In summary, our preliminary 
subtype analyses do not indicate significant differences in the genetic architectures of anorexia 
nervosa with and without binge eating; however, larger sample sizes are necessary for 
confirmation. 
 
Males with anorexia nervosa  
The number of males identified on the basis of genotype sex in the meta-analysis was 447 cases 
and 20,347 controls. Anorexia nervosa PRS scores derived using the female-only GWAS were 
associated with a higher risk of anorexia nervosa in males. Those at the highest decile had 4.13 
(95% CI: 2.58, 6.62) times the odds of lifetime anorexia nervosa compared with those at the 
lowest decile. Anorexia nervosa PRS accounted for ~1.8% of the total variance in anorexia 
nervosa in males for the discovery cohort P threshold (pT) = 0.5, comparable to ~1.7% at P 
threshold (pT) = 0.5 in the cohort as whole. Taken together, these preliminary results do not 
provide evidence for a major sex-specific difference in the common genetic architecture of 
anorexia nervosa, although our conclusions are limited due to the small sample size. 
 
Within-trait prediction: polygenic risk scoring 
 
We observed that across cohorts, anorexia nervosa cases were more likely to be in the PRS 
higher deciles than controls based on their anorexia nervosa genetic load (Supplementary Fig. 
16). Visual inspection of the decile plots showed that the score distributions across deciles were 
relatively uniform across target datasets; thus, there was no indication of any extreme outlying 
datasets. PRS applied to the largest target dataset, sedk, showed that those at the highest decile 
had 2.59 times higher odds (95% CI: 2.12-3.18) of lifetime anorexia nervosa compared with 
those at the lowest decile. The results also provide evidence of the replicability of the main 
GWAS results (Supplementary Fig. 16). 
 
Gene-wise analysis 
Results of MAGMA gene-wise associations are reported in Supplementary Table 11. Seventy-
nine genes were Bonferroni-significant (threshold = 2.62 × 10-6), and 506 had a Benjamini and 
Hochberg74 FDR q value < 0.05. None of the 79 Bonferroni-significant genes are part of the 
MHC, but 57 genes are located in a gene-rich locus on chr3. The top genes on chr3 were 
NCKIPSD, CELSR3, and IP6K2. Through the MAGMA analysis we identified 16 additional 
genes which were not annotated via clumping. These 16 genes are located in loci on chr 1, 2, 3, 
7, 10, 11, 12, 17, and 22. Some of these Bonferroni-significant genes have been indicated to be 
involved in glycemic and metabolic disease phenotypes (CTNNB175;  EXOC476; FAM19A277; 
VAMP278). 
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Pathway analysis 
 
The Bonferroni-significant pathway (Supplementary Table 12) 
GO:positive_regulation_of_embryonic_development (Gene Ontology, 32 genes, 6.31 × 10-6) has 
two Bonferroni-significant genes: DAG1 and CTNNB1. CTNNB1 encodes beta-catenin, an 
essential component of the canonical Wnt signaling pathway. Beta-catenin can regulate neuronal 
progenitor proliferation and affect cortical size79. CTNNB1 expression has been associated with 
adipogenesis, glucose metabolism, and obesity75. Metabolic diseases including obesity and type 
2 diabetes are influenced by genetic and functional variations in the Wnt signalling pathway75. 
DAG1 encodes dystroglycan, an essential member of the dystrophin-glycoprotein complex that 
has been mainly studied in the context of muscular dystrophies. Dystroglycan and other members 
of the dystrophin-glycoprotein complex are also found in neurons and glia and their disruption 
has been linked to intellectual disability and altered brain development80. Specific ablation of 
dystroglycan in neurons or glia results in distinct phenotypes81. Dystroglycan is expressed in 
pyramidal cells of the cortex and hippocampus, where it appears to be essential for the 
establishment and maintenance of CCK-positive basket cell terminals82. 
 
Tissue and cell type analyses 
 
We first used partitioned heritability analyses in LDSC using annotation of elements in the 
genome with specific functions. Considering general annotations, enrichment in conserved 
regions was the main finding (enrichment (s.e.) = 24.97 (3.29), P = 3.32 × 10-11, Supplementary 
Fig. 7). Partitioned heritability analysis was then used to test for cell type-specific enrichment in 
the GWAS of anorexia nervosa among 10 cell type groups: adrenal and pancreas; cardiovascular; 
CNS; connective and bone; gastrointestinal; immune and hematopoietic; kidney; liver; skeletal 
muscle; and other tissue (which includes adipose tissue). The CNS cell type group showed a 2.8-
fold significant enrichment (Supplementary Fig. 8).  
 
We next investigated whether there were tissue or cell type associations with anorexia nervosa 
using gene expression data to annotate gene sets characteristic of specific cells or tissues (for 
details see50). Gene expression datasets used were: GTEx (RNA-seq of samples from multiple 
human tissues); gene expression from neurons; astrocytes and oligodendrocytes from developing 
and mature mouse forebrain47; and gene expression from 149 mouse brain cell types (KI level 1: 
24 broad categories, KI level 2: 149 cell types underlying the 24 broad categories)50.  
 
Using MAGMA54, the majority of brain tissues in GTEx were significantly associated with 
anorexia nervosa (Supplementary Fig. 9), the strongest hits being brain cerebellum and brain 
cerebellar hemispheres. Enrichment in muscle-skeletal tissues also appeared likely 
(Supplementary Fig. 9). Medium spiny neurons and pyramidal neurons from the CA1 region of 
the hippocampus were significantly associated with anorexia nervosa at a Bonferroni threshold in 
the 24 level 1 cell types (Supplementary Fig. 10). Among the 149 level 2 cell types, pyramidal 
neurons from the CA1 region of the hippocampus and pyramidal neurons from the 
somatosensory cortex layer 5 were Bonferroni-significant (Supplementary Fig. 11).  
 
Medium spiny neurons (MSNs) are dopaminergic and inhibitory. They are the primary cell type 
of the striatum. The dorsal striatum has been linked to feeding behaviors including food 
27 
 
 
motivation and reward83. D1R-medium-spiny-neurons (medium spiny neurons that express the 
D1-type dopamine receptor) afferents have been reported to be the primary source of nucleus 
accumbent inhibition to the lateral hypothalamus84. Furthermore, in that study, inhibition of 
D1R-MSNs increased feeding, while activation decreased feeding84. Pyramidal neurons are 
excitatory and are the primary excitatory cell type found in cortical structures85. Kim et al.86 
recently found that PPP1R1B-expressing pyramidal neurons from the basolateral amygdala 
project to DR1-expressing central amygdala neurons, which are known to modulate appetitive 
behaviors. 
 
Using the LDSC partitioned heritability approach53, no significant signal was found in the GTEx 
database for tissues (Supplementary Figs. 12-13), in the Cahoy database for cells 
(Supplementary Fig. 14), or in the single-cell RNA-sequencing database (Supplementary Fig. 
15). Nevertheless, in GTEx, the enrichment of heritability was more common in cell types in the 
brain, although enrichment in muscle-skeletal tissues was also evident, though no cell type 
reached significance (Supplementary Fig. 13). In the Cahoy database, the enrichment appeared 
more common in astrocytes compared with neurons and oligodendrocytes, although none of 
these reached statistical significance after Bonferroni correction (Supplementary Fig. 14). In the 
single-cell RNA-sequencing database, signal was strongest in neuroblasts (Supplementary Fig. 
15). 
Predicted tissue-specific gene expression 
 
The PrediXcan analysis suggested significant effects on the expression of 36 genes across 44 
GTEx tissues (P ≤ 1.94 × 10-7; Supplementary Table 13). MGMT is located on chr10 (131.2-
131.4 Mb). The majority of others are located within the multi-genic region on chr3. 
Downregulation and upregulation are presented in Supplementary Table 13.  
 
Cross-trait analysis 
 
Genetic correlations 
Full results are shown in Supplementary Table 10 and Bonferroni-significant results are shown 
graphically in Fig. 2. In instances where the same phenotype appears in multiple study sources, 
the main manuscript and Fig. 2 report the result from the study source with the largest sample 
and/or of European ancestry.  
 
Generalized summary data-based Mendelian randomization (GSMR) 
BMI. We used GSMR87 to investigate causal associations between BMI and anorexia nervosa 
using an extension of GCTA57 (Supplementary Table 16). A one standard deviation (SD) 
decrease in genetically-estimated BMI increased the risk for anorexia nervosa by 4% (OR = 
1.04; s.e. = 0.01; PGSMR = 0.008) while an increase in genetically-estimated anorexia nervosa had 
a BMI-lowering effect (bxy = -0.28, s.e. = 0.07, PGSMR = 5.15 × 10-5). We only used eight SNPs 
to build the multiple SNP instrument for anorexia nervosa as an exposure and, hence, these 
results should be interpreted with caution.  
 
To further separate effects of BMI from the anorexia nervosa phenotype, we used GCTA-
mtCOJO57,87 (multi-trait-based conditional & joint analysis using GWAS summary data) to 
adjust the anorexia nervosa GWAS summary statistics for BMI, using BMI summary statistics 
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from our UK Biobank analysis, which excluded individuals with a mental health diagnosis or 
taking a psychiatric or weight changing medication (see Additional Methods) and re-ran the 
GSMR analysis. The anorexia nervosa and BMI GWAS were performed on independent 
samples. As expected, after conditioning on BMI, the bidirectional pattern was no longer 
observable with ORBMI→AnorexiaNervosaAdjBMI = 1.00 (s.e. = 0.01; PGSMR = 0.78). However, the 
putative causal association from AnorexiaNervosaAdjBMI to BMI was still statistically 
significant (bxy = -0.22, s.e. = 0.08, PGSMR = 0.004). The results are consistent with a causal 
relationship not due to pleiotropy (in the case of the anorexia nervosa→BMI effect) between 
these two traits. 
 
Type 2 diabetes. We also investigated the causal relationship between Type 2 diabetes and 
anorexia nervosa using GSMR. The association with Type 2 diabetes as an exposure and 
anorexia nervosa as an outcome was not statistically significant (bxy = -0.02, s.e. = 0.03, PGSMR 
= 0.035), nor was the association with anorexia nervosa as an exposure and Type 2 diabetes as an 
outcome (bxy = -0.09, s.e. = 0.09, PGSMR = 0.30). These results do not support either phenotype 
as having a putative causal effect on the other. The analysis with anorexia nervosa as an 
exposure had only 7 instrumental variables rather than the recommended minimum of 10, 
therefore results are to be interpreted cautiously and may change once the anorexia nervosa 
GWAS sample size increases.   
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